UC Davis UC Davis Previously Published Works

Title

The Frequency of Symptoms in Patients With a Diagnosis of Degenerative Cervical Myelopathy: Results of a Scoping Review.

Permalink https://escholarship.org/uc/item/7kk9d2k9

Journal Global Spine Journal, 14(4)

ISSN

2192-5682

Authors

Jiang, Zhilin Davies, Benjamin Zipser, Carl et al.

Publication Date

2024-05-01

DOI

10.1177/21925682231210468

Peer reviewed



The Frequency of Symptoms in Patients With a Diagnosis of Degenerative Cervical **Myelopathy: Results of a Scoping Review**

Global Spine Journal 2024, Vol. 14(4) 1395-1421 © The Author(s) 2023 Article reuse guidelines: sagepub.com/iournals-permissions DOI: 10.1177/21925682231210468 journals.sagepub.com/home/gsj S Sage

Zhilin Jiang, BA, MBBS¹, Benjamin Davies, BSc, MPhil, MRCS², Carl Zipser, MD, FEBN³, Konstantinos Margetis, MD, PhD⁴, Allan Martin, MD, PhD⁵, Stavros Matsoukas, MD⁴ Freschta Zipser-Mohammadzada, PhD³, Najmeh Kheram, MSc^{3,6}, Andrea Boraschi, MSc⁶, Elina Zakin, MD⁷, Oke Righteous Obadaseraye, MBBS, MCh Ortho(UK), FMCOrtho⁸, Michael G. Fehlings, MD, PhD, FRCSC⁹, Jamie Wilson, MD¹⁰, Ratko Yurac, MD¹¹, Chad E. Cook, PT, PhD, MBA, FAPTA¹², Jamie Milligan, MD¹³, Julia Tabrah, BSc(Hons), MSc¹⁴, Shirley Widdop, BSc¹⁵, Lianne Wood, PhD¹⁶, Elizabeth A. Roberts, MA (Oxon), MSc (Edin)¹⁵, Tanzil Rujeedawa, BA², Lindsay Tetreault, MD, PhD⁷, and AO Spine RECODE-DCM Diagnostic Criteria Incubator

Abstract

Study Design: Delayed diagnosis of degenerative cervical myelopathy (DCM) is associated with reduced quality of life and greater disability. Developing diagnostic criteria for DCM has been identified as a top research priority.

Objectives: This scoping review aims to address the following questions: What is the diagnostic accuracy and frequency of clinical symptoms in patients with DCM?

Methods: A scoping review was conducted using a database of all primary DCM studies published between 2005 and 2020. Studies were included if they (i) assessed the diagnostic accuracy of a symptom using an appropriate control group or (ii) reported the frequency of a symptom in a cohort of DCM patients.

⁵ Department of Neurosurgery, University of California Davis, Davis, CA, USA

⁷ Department of Neurology, New York UniversityLangone, New York, NY, USA

Corresponding Author:

Elizabeth A. Roberts, Myelopathy.org, Pioneer House, Vision Park, Histon, Cambridge CB24 9NL, UK. Email: recode@myelopathy.org



Creative Commons Non Commercial No Derivs CC BY-NC-ND: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

¹ King's College Hospital, NHS Foundation Trust, London, UK

² University of Cambridge, Cambridge, UK

³ Spinal Cord Injury Center, Balgrist University Hospital, Zurich, Switzerland

⁴ Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁶ The Interface Group, Institute of Physiology, University of Zurich, Zurich, Switzerland

⁸ Department of Surgery, Asaba Specialist Hospital, Asaba, Nigeria

⁹ Division of Neurosurgery and Spinal Program, University of Toronto, Toronto, ON, Canada

¹⁰ University of Nebraska Medical Center, Omaha, NE, USA

¹¹ Professor of Orthopedics and Traumatology, University del Desarrollo, Clinica Alemana de Santiago, Santiago, Chile

¹² Duke University Medical Center, Durham, NC, USA

¹³ Department of Family Medicine, McMaster University, Hamilton, ON, USA ¹⁴ Hounslow and Richmond Community Healthcare, London, UK

¹⁵ Myelopathy.org, Cambridge, UK

¹⁶ Nottingham University Hospital, Nottingham, UK

Results: This review identified three studies that discussed the diagnostic accuracy of various symptoms and included a control group. An additional 58 reported on the frequency of symptoms in a cohort of patients with DCM. The most frequent and sensitive symptoms in DCM include unspecified paresthesias (86%), hand numbness (82%) and hand paresthesias (79%). Neck and/or shoulder pain was present in 51% of patients with DCM, whereas a minority had back (19%) or lower extremity pain (10%). Bladder dysfunction was uncommon (38%) although more frequent than bowel (23%) and sexual impairment (4%). Gait impairment is also commonly seen in patients with DCM (72%).

Conclusion: Patients with DCM present with many different symptoms, most commonly sensorimotor impairment of the upper extremities, pain, bladder dysfunction and gait disturbance. If patients present with a combination of these symptoms, further neuroimaging is indicated to confirm the diagnosis of DCM.

Keywords

1396

degenerative disc disease, cervical, myelopathy

Introduction

Degenerative cervical myelopathy (DCM) is a progressive spine disease and the most common cause of spinal cord impairment worldwide.^{1,2} In several countries, the pathway to the diagnosis of DCM typically starts at the level of the primary care physician or non-spine specialist. Unfortunately, DCM is underrepresented in medical school or postgraduate curricula, commonly used textbooks and question banks.³ Furthermore, only 45% of myelopathy symptoms entered into Web-based symptom checkers include DCM as a differential diagnosis.⁴ Individuals are therefore unlikely to consider DCM when or before presenting to their primary care physician.

Consequently, diagnosis of DCM is often delayed. A recent study by Hilton et al⁵ (2019) investigated the pathway from symptom onset to surgical assessment in the United Kingdom healthcare system. Based on their results, the time between symptom onset and referral by a primary care physician was 8.3 ± 10.1 months for new cases of DCM, representing the greatest delay in the diagnostic pathway. Furthermore, seventy-six percent of new cases were initially referred to a speciality other than spinal surgery such as neurology, pain management, rheumatology and geriatrics. Ultimately, the mean time between symptom onset and surgical evaluation was 17.7 ± 16.0 months. This delay in assessment by a qualified spine provider can have a deleterious effect on neurological and functional recovery following surgery.⁶ For instance, based on a study by Pope et al' (2020), patients whose diagnosis was made 1-2 years after presentation were more likely to be unable to work and further delays resulted in increased dependence on others for activities of daily living. Additionally, myelopathy severity, duration of symptoms and gait dysfunction are significant predictors of worse surgical outcome, making early detection, as well as identification of milder patients, a priority.⁶ Furthermore, DCM results in an estimated annual loss of productivity of £362.6 m, costs £280.2 m in disability benefits and imposes an overall cost to society of £681.6 m. The direct and indirect costs of managing patients with DCM could be reduced with accurate and timely diagnosis.⁸ Therefore, it is imperative to shorten the time to diagnosis and improve the pathway of care to definitive management in order to optimize patient outcomes and reduce lifelong disability.

Misdiagnosis or delayed diagnosis of DCM is likely due to the variety of clinical presentations, incomplete neurological examinations by clinicians and reduced awareness of this condition. As DCM results from compression of the cervical spinal cord, patients present with a wide range of sensory and motor complaints in their upper and lower extremities as well as evidence of autonomic dysfunction.⁹⁻¹¹ Common complaints include bilateral arm paresthesia, reduced manual dexterity, impaired gait and weakness.¹⁰ Other symptoms (a manifestation of disease apparent to the patient) include neck pain or stiffness, Lhermitte's phenomena and urgency of urination or defection. On physical examination, patients with DCM exhibit a combination of upper and lower motor neuron signs as well as impaired sensation to light touch, temperature, proprioception, vibration and pain.

Given that there is no single clinical feature or test that is sufficient to diagnose DCM, developing diagnostic criteria for this condition would be invaluable. Diagnostic criteria for DCM could (i) improve patient care by facilitating earlier diagnosis and treatment, (ii) act as reference for primary care physicians, allied health professionals and other specialists who encounters these patients and (iii) serve as a basis for developing a triaging and surveillance system. As part of the AO Spine RECODE-DCM (Research Objectives and Common Data Elements for Degenerative Cervical Myelopathy) project, establishing diagnostic criteria was identified as one of the top ten priorities for future research.^{12,13} The first step in this process is to determine candidate variables for inclusion in diagnostic criteria. Symptoms that are frequently reported in patients with DCM and exhibit high sensitivity and specificity are important to identify.

The objective of this study is to conduct a scoping review of the literature in order to address the following key questions (KQ): KQ1: What is the diagnostic accuracy (ie sensitivity, specificity, positive or negative predictive value, positive or negative likelihood ratio) of clinical symptoms in patients with DCM?

KQ2: What is the frequency of clinical symptoms in patients with DCM?

Methods

A scoping review was conducted to assess the diagnostic accuracy of clinical symptoms in patients with DCM. The scoping review was formatted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist.¹⁴ A systematic review was not performed as the evidence on the diagnostic accuracy of symptoms is limited. Neither informed consent nor Institutional Review Board approval were required due to the nature of the study.

Eligibility Criteria

Table 1 summarizes the inclusion and exclusion criteria in terms of population of interest, clinical symptoms, outcomes and study design.

Population

This review targeted at studies on adult patients (>18 years) with cervical myelopathy secondary to spondylosis, disc herniation, ossification of the posterior longitudinal ligament (OPLL), congenital stenosis or subluxation. Eligible studies consisted of patients treated surgically or managed

Table I. Inclusion and Exclusion Criteria.

conservatively. Studies were excluded if they included patients with traumatic spinal cord injury, thoracic or lumbar myelopathy, tumor or infection.

Clinical Symptoms

Studies were included if they assessed the diagnostic accuracy or reported the frequency of clinical symptoms in DCM. Symptoms of interest included, but were not limited to, hand numbness, loss of dexterity, arm paresthesias, gait impairment, weakness, neck pain and bladder or bowel dysfunction. Studies were excluded if they only discussed clinical signs, patient- or clinician-reported outcome measures or imaging characteristics.

Outcome

Studies were included if they summarized the sensitivity, specificity, positive or negative predictive value or positive or negative likelihood ratio of a symptom. In some cases, sensitivity was calculated from the frequency of a clinical sign in a DCM population.

Study Design

For KQ1, this review targeted cohort, case-control or casebased studies that included an acceptable control group for comparison. An example of an appropriate control group is a group of individuals with cervical radiculopathy or axial neck pain with no evidence of myelopathy or cord compression. For KQ2, this review identified clinical studies that reported the frequency of various symptoms in patients with DCM. Studies

Characteristic	Inclusion	Exclusion
Population	 Patients with cervical myelopathy secondary to spondylosis, disc herniation, ossification of the posterior longitudinal ligament, congenital stenosis or subluxation. Managed conservatively or surgically. Age >18 years 	- Patient with traumatic spinal cord injury, thoracic or lumbar myelopathy, tumor or infection.
Symptoms	- Numb hands Clumsy hands	- Clinical signs on physical examination - Patient reported outcome measures (eg neck disability
	- Arm paresthesia	index, SF-36, VAS, subjective questionnaires)
	- Neck pain	- Clinician reported outcome measures (eg mJOA,
	- Shoulder or arm pain - Weakness	Nurick, walking test, grip dynamometer, GRASSP, GaitRite)
	- Gait disturbances	- Imaging characteristics
	 Bladder or bowel dysfunction 	
Outcome	KQ1: Sensitivity, specificity, positive or negative predictive,	- Reliability
	positive or negative likelihood ratio	- Responsiveness to change
	KQ2: Frequency, percentages	- Internal consistency
Study design	KQ1: Case-control or cohort studies. Acceptable control group for comparison (eg individuals with cervical radiculopathy or axial neck pain with no myelopathic symptoms) KQ2: Clinical trial or cohort studies that reported the frequency of	 Systematic or narrative reviews Animal or biomechanical studies
	symptoms in the studied population	- Studies without an acceptable control group

were excluded if they were commentaries or opinions, systematic or narrative reviews, animal or biomechanical studies or consisted of less than 15 participants (patients or healthy controls).

Search, Study Selection and Data Collection Process

In Davies et al (2018) established and validated a highly sensitive MEDLINE search filter for DCM in order to optimize literature reviews.^{15,16} Using this filter, a database was developed that includes all primary studies on DCM. For this scoping review, this database was accessed to identify all DCM papers published between 2005 and 2020. Only studies involving humans and written in English were considered for inclusion. Full text investigation of each study in the database was deemed necessary as the frequency of clinical symptoms of DCM may be reported in the methods or results section without being referred to in the abstract. The following data were extracted from each article: patient sample and characteristics, including diagnosis and treatment; relevant symptoms; and results on frequency and diagnostic accuracy.

Risk of Bias in Individual Studies

Risk of bias was not assessed given this was a scoping review and not a systematic review.¹⁴ Furthermore, studies were not excluded based on risk of bias given the known paucity and heterogeneity of the evidence base.

Data Analysis

Forest plots were created using RevMan. From each article, we extracted the number of patients who had the disease and tested positive (true positive), did not have the disease and tested positive (false positive), had the disease and tested negative (false negative), and did not have the disease and tested negative (frue negative). From these values, sensitivity and specificity were computed and plotted. In some studies, we estimated each value using prevalence data in combination with reported sensitivity and specificity. In other studies, only true positives were reported. The 95% confidence intervals for sensitivity and specificity were automatically generated by RevMan using standard error.

Results

Study Selection

The search yielded a total of 1674 citations. Two-hundred and five duplicate studies were removed. The full text of 46 studies could not be located. After full text review, 1361 records were excluded. Three studies explored the diagnostic accuracy of common symptoms of DCM using an appropriate control group.¹⁷⁻¹⁹ An additional 58 studies reported on frequency of clinical signs in a cohort of DCM patients and were also

included.^{6,19-75} Commonly, studies were excluded if they (i) discussed cervical spine pathology in asymptomatic individuals; (ii) included patients with both myelopathy and radiculopathy or myelopathy secondary to trauma, tumor or infection; (iii) were systematic or narrative reviews, surveys, posters or editorials; (iv) assessed the diagnostic accuracy of patient- or clinician-reported outcome measures; (v) had fewer than 15 patients; and (vi) were based on animal or computational models (Figure 1).

Study Characteristics

For KQ1, the search identified three studies that discussed the diagnostic accuracy of various symptoms and included a control group (Tables 2 and 3, Figure 2).¹⁷⁻¹⁹ Sample sizes ranged from 33 to 100. The most commonly reported symptom was neck pain (n = 2).^{18,19} All other symptoms were reported by single studies. Control groups included patients with signs and symptoms of early cervical myelopathy or cervical spine pain without evidence of cord compression or T2-signal change on MRI. For KQ2, an additional 58 studies were identified that reported on the frequency of symptoms in a cohort of patients with DCM (Table 4, Figures 3-8).^{6,19-74,76}

Results of Individual Studies

Studies That Included a Control Group. Cook et al (2009) compared the frequency of various symptoms between patients with hyperintensity on T2-weighted MRI and those without signal change. Based on their results, the most sensitive symptom for diagnosing myelopathy was current neck pain (94%), followed by loss of dexterity (72%), numbress in hands (56%) and clumsiness during gait (56%).¹⁹ In contrast, neck pain (18%) and loss of dexterity (26%) had poor specificity. Finally, based on likelihood ratios, none of these four stand-alone symptoms demonstrated the ability to influence post-test probability with a positive or a negative finding. Cheung et al¹⁸ (2018) evaluated the frequency of neck or shoulder pain in patients with and without DCM. Based on their results, the sensitivity of neck pain for diagnosing cervical myelopathy was 76% and the specificity was 11%. Finally, Hori et al¹⁷ (2012) separated patients with clinical signs and symptoms of early cervical myelopathy into two groups based on whether their spinal cord was compressed or not on MRI. The presence of numbress and pain was moderately sensitive (61%) and specific (60%) for diagnosing DCM. All other symptoms had low sensitivity but high specificity, including cervical vertigo (6%, 87%), neck stiffness (11%, 87%), hyperalgesia (6%, 87%), tremor (11%, 93%), jitteriness (0%, 93%) and apraxia (6%, 93%) (Tables 2 and 3, Figure 2)

Studies That Reported on the Frequency of Symptoms in Patients With Degenerative Cervical Myelopathy

Symptoms Related to Gait. Twenty-three studies discussed the frequency of gait dysfunction in patients with






Figure 1. An overview of the search process.

DCM.^{6,23,25,26,28,30,32,33,38-41,48,51,52,56,66-68,70,71,73,74} Based on their results, the sensitivity of gait impairment for diagnosing DCM ranged from 10% to 100% with a weighted average of 72% (95% CI 70%-74%). In three studies, all patients reported a degree of gait instability or dysfunction.^{32,40,66} In single studies, the frequency of walking fatigue and difficulty climbing was 40% and 70%, respectively.^{64,69} Finally, rates of imbalance ranged from 4% to 25%.^{30,31,71}

Symptoms Related to Pain. Several studies reported on the frequency of various types of pain in patients with DCM: radicular or radiating (n = 12),^{20,24,25,31,34,48,49,59,61,66,67,75} neck and/or shoulder (n = 27),^{20,23,25,28,30-32,34-36,42,46,47,49,51-54,56,57,61,64,65,67, 71,73,74} upper extremity (n = 5),^{26,36,52,57,65} axial (n = 5),^{27,40,44,65,72}

back (n = 2)^{31,45} or unspecified (n = 2) pain.^{29,68} Furthermore, single studies presented the incidence of lower extremity pain,⁵² funicular pain,²⁵ chest and/or abdominal discomfort⁴⁸ and headache.⁶⁷ A study by Niu et al⁵⁷ (2020) aimed to summarize the primary complaints as well as other symptoms experienced by patients undergoing surgery for DCM. Based on their results, neck pain was the chief complaint in 33% of patients, while upper extremity pain was the chief complaint in 37%. Interestingly, upper extremity pain was more common when the level of maximal spinal cord compression was more distal in the cervical spine. The frequency of different types of pan varied significantly across studies: (i) 7%-93% for radicular pain (weighted average: 39%, 95% CI 35%-42%); (ii) 9%-100% for neck and/or shoulder pain (weighted average: 51%, 95% CI 49%-53%); (iii) 10%-54% for upper extremity pain (weighted average: 43%, 95% CI

Author (Year), Study Design	Objective	Cervical Myelopathy and Control Group	Demographic Information	Symptoms	Metrics of Diagnostic Accuracy Assessed
Cheung et al (2018)	To translate and cross-culturally adapt the JOACMEQ into Traditional Chinese and to assess its validity, reliability and sensitivity for differentiating cervical myelopathy and presence of acute neck/shoulder pain	Cervical myelopathy group (n = 63) - Patients with cervical myelopathy secondary to CSM, OPLL and cervical subluxation or dislocation Control group (n = 37) - Patients without cervical myelopathy		Neck/ shoulder pain	Sensitivity Specificity Positive and negative predictive value Positive and negative likelihood ratio
Cook et al (2009), prospective	To assess reliability and diagnostic accuracy of neurological tests and subjective findings associated with cervical myelopathy.	Cervical myelopathy group (n = 18) - Primary complaint of cervic spine pain with signal intensity changes on MRI confirming the presence of myelomalacia Control group (n = 27) - Primary complaint of cervic spine pain without MRI evidence of myelomalacia	of al	Neck pain Loss of dexterity Hand Humbness Gait clumsiness	Sensitivity Specificity Positive and negative predictive value Positive and negative likelihood ratio
Hori et al (2012)	To use novel diffusion metrics to estimate spinal cord compression in patients with early cervical spondylosis.	•	Cervical myelopathy Age: 63.3 ± 10.8 Men: 33% Control Age: 50.5 ± 16.2 Men: 47%	Numbness Pain Cervical vertigo Neck stiffness Hypalgesia Tremor Apraxia Jitteriness	Sensitivity Specificity Positive and negative predictive value Positive and negative likelihood ratio

myelopathy but without spinal cord compression

Table 2. Summary of Studies That Included a Control Group and Assessed the Diagnostic Accuracy of Various Clinical Symptoms.

40%-46%); and (iv) 19%-100% for axial pain (pain extending from the nuchal to scapular regional, weighted average 41%, 95% CI 35%-46%). Only a minority of patients with DCM reported headache (8%), lower extremity pain (10%) or back pain (9-22%).

Symptoms Related to Hand and Upper and Lower Extremity Motor Function. Several studies reported on the frequency of symptoms related to hand function in patients with DCM. Rates of hand clumsiness ranged from 26% to 90% across ten studies with a weighted average of 69% (95% CI 67%-72%).^{6,25,26,28,40,41,54,64,70} Hand function was also described in terms of loss of dexterity and fine motor disturbance in five studies.^{38,39,67,69,71} In two studies by Holly et al (2009, 2017), 63%-71% of patients reported significant changes in their ability to use utensils, sew, write or do up buttons.^{38,39} Similarly, Thakar et al⁶⁴ (2009) determined that 54% of patients experience difficulty eating, potentially due to difficulty manipulating a fork and knife. The frequency of deterioration in hand function was lower in three other studies and ranged from 22% to 53%.^{67,69,71} Cole et al³¹ (2020) reported 85% of patients with DCM had at least one hand symptom, either pain, numbness, weakness or loss of dexterity. Finally, across two studies, the frequency of hand weakness ranged from 4% to 18%.^{28,30}

Twelve studies discussed the frequency of upper extremity motor symptoms.^{21,25,26,28,30,31,33,47,57,59,67,71} In a single study by Cui et al³⁰ (2015), clumsiness of the upper limb was much less frequent (4%) among patients with DCM than hand clumsiness (26%). The frequency of upper extremity weakness ranged from 4% to 92% across 12 studies with a weighted average of 58% (95% CI 55%-60%). In Niu et al⁵⁷ (2020), while upper extremity weakness was present in 83% of patients with DCM, it was the chief complaint in only 34%.

Similarly, ten studies reported rates of lower extremity motor symptoms in patients with DCM.^{21,25,30,33,47,52,57,59,67,71} Rates of lower extremity weakness ranged from 3% to 88% with a

Clinical Symptom	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)	Positive Likelihood Ratio	Negative Likelihood Ratio
Gait clumsiness						
Cook et al (2009)	56	52	43	54	1.15	.86
Loss of dexterity						
Cook et al (2009)	72	26	39	58	.98	1.07
Hand numbness						
Cook et al (2009)	56	67	53	69	1.67	.67
Neck pain						
Cheung et al (2018)	76	11	59	21	.85	2.20
Cook et al (2009)	94	18	44	83	1.16	.30
Numbness						
Hori et al (2012)	61	60	65	56	1.53	.65
Pain						
Hori et al (2012)	61	60	65	56	1.53	.65
Cervical vertigo						
Hori et al (2012)	6	87	33	43	.42	1.09
Neck stiffness						
Hori et al (2012)	11	87	50	45	.83	1.02
Hypalgesia						
Hori et al (2012)	6	87	33	43	.42	1.09
Tremor						
Hori et al (2012)	11	93	67	47	1.67	.95
Jitteriness						
Hori et al (2012)	0	93	0	44	.00	1.07
Apraxia						
Hori et al (2012)	6	93	50	45	.83	1.01

Table 3. Diagnostic Accuracy of Symptoms in Degenerative Cervical Myelopathy: Results of Three Studies That Included a Control Group.

weighted average of 54% (95% CI 51%-57%). An additional ten studies were identified that did not distinguish between weakness affecting the upper and lower extremities.^{6,22,23,25,34,50,51,58,61,70} Across these studies, the frequency of weakness ranged from 15% to 97% with a weighted average of 75% (95% CI 72%-77%).

Symptoms Related to Hand and Upper and Lower Extremity Sensory Function. Eleven studies reported on the frequency of sensory hand complaints in patients with DCM: numbness (n = 6),^{6,30,31,48,69,70} paresthesias (=2)^{28,56} and unspecified (numbness or paresthesias, n = 3).³⁸⁻⁴⁰ Based on their results, the frequency of hand numbness ranged from 21% to 89% (weighted average: 82%, 95% CI 80%-85%) while the frequency of hand paresthesias ranged from 24% to 93% (weighted average: 79%, 95% CI 68%-87%). In two studies by Holly et al (2009, 2017), 44%-48% of patients reported hand sensory symptoms, whereas in a third study by Hossam et al (2013), all patients had either hand numbness or paresthesias.³⁸⁻⁴⁰

Based on the results of seven studies, the sensitivity of upper extremity numbress for diagnosing DCM ranged from 4% to 96% with a weighted average of 69% (95% CI 66%-72%)^{28-30,52,54,64,71} Similarly, the frequency of upper extremity paresthesias ranged from 29% to 70% (weighted average 57%, 95% CI 54%-60%).^{6,28,67,68,70} In a study

Gait clumsiness TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study Cook 2009 10 13 8 14 0.56 [0.31, 0.78] 0.52 [0.32, 0.71] 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Loss of dexterity Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Cook 2009 13 20 57 0.72 [0.47, 0.90] 0.26 [0.11, 0.46] 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Hand Numbness Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 0.56 [0.31, 0.78] 0.67 [0.46, 0.83] Cook 2009 10 9 8 18 Neck Pain +/- shoulder pain Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study TP FP FN TN *Weighted Average 65 55 16 9 0.80 [0.70, 0.88] 0.14 [0.07, 0.25] -Cheung 2018 48 33 15 4 0.76 [0.64, 0.86] 0.11 [0.03, 0.25] Cook 2009 17 22 1 5 0.94 [0.73, 1.00] 0.19 [0.06, 0.38] 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Numbness Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 9 0.61 [0.36, 0.83] 0.60 [0.32, 0.84] Hori 2012 6 11 7 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Pain Sensitivity (95% CI) Specificity (95% CI) Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Hori 2012 11 6 7 9 0.61 [0.36, 0.83] 0.60 [0.32, 0.84] 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 **Cervical Vertigo** Sensitivity (95% CI) Specificity (95% CI) TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Study Hori 2012 2 17 13 0.06 [0.00, 0.27] 0.87 [0.60, 0.98] 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Neck Stiffness Sensitivity (95% CI) Specificity (95% CI) Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Hori 2012 2 16 13 0.11 [0.01, 0.35] 0.87 [0.60, 0.98] 2 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Hypalgesia Study TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 2 17 13 0.06 [0.00. 0.27] 0.87 [0.60, 0.98] Hori 2012 1 └── | | | | | | | | | | | | | | | | 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Tremor TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study Hori 2012 1 16 14 0.11 [0.01, 0.35] 0.93 [0.68, 1.00] 2 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Jitteriness TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study Hori 2012 1 18 14 0.00 [0.00, 0.19] 0.93 [0.68, 1.00] 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Apraxia TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study Hori 2012 1 1 17 14 0.06 [0.00, 0.27] 0.93 [0.68, 1.00] 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1 Bowel and bladder symptoms TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Study Lieberman 2019 54 62 40 86 0.57 [0.47, 0.68] 0.58 [0.50, 0.66] 0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1

Figure 2. Sensitivity and specificity of symptoms in degenerative cervical myelopathy: Results of three studies that included a control group.

by Niu et al⁵⁷ (2020), the most common chief complaint was upper extremity sensory symptoms (46%); however, it was the third most common overall symptom (71%). Finally, any upper extremity sensory complaint was present in 71%-78% of patients with DCM.^{26,47}

Nine studies discussed the frequency of lower extremity sensory symptoms in a DCM population: numbness (n = 5), 30,54,64,67,71 paresthesias $(n = 1)^{67}$ and unspecified (n = 4). 26,39,47,57 The sensitivity of lower extremity numbness ranged from 17% to 91% with a weighted mean of 61% (95% CI

Clinical Symptom	Sensitivity	Clinical Symptom	Sensitivity	
Autonomic symptoms				
Bowel/bladder complaints		Sexual dysfunction		
Ahmed et al (2020)	Sphincter disturbance: 43%	Chibbaro et al (2009)	6%	
Audat et al (2018)	16%	He et al (2006)	3%	
Burkhardt et al (2017)	Bladder: 4%	Sinha and Jagetia (2011)	6%	
Chacko et al (2012)	Bladder: 33%			
Chacko et al (2014)	Bladder: 42%			
Chatley et al (2009)	Bladder: 42%, bowel: 33%			
Chibbaro et al (2009)	13%			
El-Ghandour et al (2020)	Bladder: 42%			
Holly et al (2009)	10%			
Holly et al (2017)	13%			
Hossam et al (2013)	Sphincter disturbance: 100%			
Jain et al (2009)	30%			
Kang et al (2020)	9%			
Kim et al (2007)	Sphincter disturbance: 19%			
Kim et al (2010)	Bladder: 17%, bowel: 6%			
Kim et al (2018)	Bladder: 13%			
Kommu et al (2014)	Sphincter disturbance: 21%			
Lo (2007)	Sphincter disturbance: 7%			
Misawa et al (2005)	Bladder: 52%			
Moussellard et al (2014)	Bladder: 58%			
Niu et al (2020)	Sphincter disturbance: CC: 1%, OS 17%			
Raslan et al (2014)	Sphincter disturbance: 10%			
Revanapa et al (2017)	Bladder: 68%			
Scholler et al (2020)	5%			
Sinha and Jagetia (2011)	12%			
Turel et al (2013)	Bladder: 21%			
Williams et al (2009)	Bladder: 17%			
Zhang et al (2018)	21%			
Gait dysfunction and imbalance				
Gait dysfunction		Difficulty climbing		
Burkhardt et al (2017)	87%	Thakar et al (2009)	70%	
Chatley et al (2009)	86%			
Chibbaro et al (2009)	76%			
Choi and Kim (2018)	12%			
Cui et al (2015)	35%			
Dong et al (2018)	100%			
Du et al (2013)	57%			
Holly et al (2009)	76%			
Holly et al (2017)	69%			
Hossam et al (2013)	100%			
Hou et al (2020)	53%			
Kim et al (2007)	77%			
Kong et al (2019)	25%			
Konya et al (2009)	10%			
Moussellard et al (2014)	79%			
Tetreault et al (2015)	77%			
Turel et al (2013)	100%			
Vitzthum and Dalitz (2007)	86%			
Wei et al (2019)	55%			
Williams et al (2009)	83%			
Zhang et al (2018)	72%			
Zhou et al (2015)	42%			
Zhou et al (2018)	56%			

Table 4. Frequency of Symptoms in Patients With Degenerative Cervical Myelopathy.

(continued)

Table 4. (continued)

Clinical Symptom	Sensitivity	Clinical Symptom	Sensitivity
Walking fatigue		Imbalance	
		Cole et al (2020)	12%
Wang et al (2012)	40%	Cui et al (2015)	4%
		Zhang et al (2018)	Gait: 25%
Pain symptoms			
Radicular/Radiating pain		Neck and/or shoulder pain	
Audat et al (2018)	96%	Audat et al (2018)	98%
Chacko et al (2012)	14%	Burkhardt et al (2017)	83%
		Chatley et al (2009)	39%
		Choi and Kim (2018)	Neck or shoulder: 24%
		Cole et al (2020)	33% 9%
		Cui et al (2015) Dans et al (2018)	
		Dong et al (2018) El Chandour et al (2020)	Neck and shoulder: 100% 75%
		El-Ghandour et al (2020) Gembruch et al (2019)	Neck and arm: 40%
		Gerling et al (2017)	51%
		Jain et al (2009)	100%
		Kim et al (2010)	50%
Chacko et al (2014)	15%	Kim et al (2018)	19%
Chatley et al (2009)	27%	· /	
Cole et al (2020)	9%	Kiris and Kilincer (2008)	38%
	770	Kong et al (2019)	100%
		Konya et al (2009)	Neck and arm: 90%
		Lau et al (2017)	66%
		Lo (2007)	35%
El-Ghandour et al (2020)	51%	Moussellard et al (2014)	52%
		Niu et al (2020)	CC: 33%, OS 55%
		Scholler et al (2020)	75%
		Thakar et al (2009)	44%
		Thakar and Rajshekhar (2012)	43%
Kim et al (2007)	35%	Williams et al (2009)	54%
Kiris and Kilincer (2008)	20% (radicular symptoms)	Zhang et al (2018)	21%
Raslan et al (2014)	38%	Zhou et al (2015)	Neck or shoulder: 39%
Scholler et al (2020)	50%	Zhou et al (2018)	Neck or shoulder: 72%
Turel et al (2013)	7%		
Williams et al (2009)	79%		
Jpper limb pain		Axial pain	
Chibbaro et al (2009)	26%	Cho et al (2010)	100%
Gerling et al (2017)	45%	Hossam et al (2013)	87%
Konya et al (2009)	10%	Kato et al (2008)	19%
Niu et al (2020)	CS: 37%, OS: 54%	Thakar and Rajshekhar (2012)	24%
Thakar and Rajshekhar (2012)	51%	Zhang et al (2020)	54%
	51%	Lower limb pain	578
Back pain Cole et al (2020)	9%		10%
()		Konya et al (2009)	10%
Kawakita et al (2009)	Lower: 22%		
Unspecified pain	2.49/	Funicular pain	F0/
Chiu and Pang (2017)	24%	Chatley et al (2009)	5%
Vitzthum and Dalitz (2007)	67%		
Headache		Chest/Abdominal discomfort	
Williams et al (2009)	8%	Kim et al (2007)	58%
Spasm			
Konya et al (2009)	Paravertebral: 90%		
Motor symptoms			
Hand clumsiness		Loss of hand Function/Fine motor	
Chatley et al (2009)	73%	disturbance	
		Holly et al (2009)	71%
Chibbaro et al (2009)	56%	Holly et al (2017)	63%
Choi and Kim (2018)	47%	Wang et al (2012)	53%

(continued)

۲V Table

Clinical Symptom	Sensitivity	Clinical Symptom	Sensitivity
Cui et al (2015)	26%	Williams et al (2009)	33%
Hossam et al (2013)	90%	Zhang et al (2018)	22%
Hou et al (2020)	67%		22/0
	72%		
Lo (2007)			
Tetreault et al (2015)	75%		
Thakar et al (2009)	80%		
Wei et al (2019)	55%		
Any hand symptom (pain, numbness,		Any upper extremity symptom (weakness,	
weakness or loss of dexterity)	05%	sensory loss or loss of dexterity)	68%
Cole et al (2020)	85%	Zhou et al (2015)	
		Zhou et al (2018)	61%
Difficulty eating	F 40/	Unspecified fine motor difficulties	20%
Thakar et al (2009)	54%	Gerling et al (2017)	28%
Hand weakness	100/	Foot weakness	100/
Choi and Kim (2018)	18%	Konya et al (2009)	10%
Cui et al (2015)	4%		
Upper extremity clumsiness		Lower extremity clumsiness	
Cui et al (2015)	4%	Cui et al (2015)	4%
Upper extremity weakness		Lower extremity weakness	
		Ahmed et al (2020)	63%
Ahmed et al (2020)	87%	Chatley et al (2009)	3%
Chatley et al (2009)	16%	Cui et al (2015)	4%
Chibbaro et al (2009)	66%	Du et al (2013)	29%
Choi and Kim (2018)	47%	Kim et al (2018)	41%
Cole et al (2020)	12%	Konya et al (2009)	10%
		Niu et al (2020)	CC: 29%, OS: 81%
Cui et al (2015)	4%	Raslan et al (2014)	33%
Du et al (2013)	58%	Williams et al (2009)	88%
Kim et al (2018)	19%	Zhang et al (2018)	43%
Niu et al (2020)	CC: 34%, OS: 83%		
Raslan et al (2014)	43%		
Williams et al (2009)	92%		
Zhang et al (2018)	38*		
Weakness			
Asher et al (2019)	55%		
Burkhardt et al (2017)	57%		
Chatley et al (2009)	Mean: 78%, all 4 limbs: 48%		
El-Ghandour et al (2020)	91%		
Kommu et al (2014)	97%		
Kong et al (2019)	50%		
Rajashekaran et al (2016)	23%		
Scholler et al (2020)	15%		
Tetreault et al (2015)	83%		
Wei et al (2019)	73%		
· · · ·	, 370		
Sensory symptoms		Lower extremity numbrase	
Jpper extremity numbness	11%	Lower extremity numbness	17%
Chiu and Pang (2017)	44%	Cui et al (2015)	65%
Choi and Kim (2018)	6% 4%	Lo (2007) Thakar at al (2009)	
Cui et al (2015)	4%	Thakar et al (2009)	91% 92%
Konya et al (2009)	60%	Williams et al (2009) Then s at al (2010)	83%
Lo (2007)	83%	Zhang et al (2018)	57%
Thakar et al (2009)	Hands and arms: 96%		
Zhang et al (2018)	74%		
Hand numbriess		I Inspecified numbress	

ŀ Hand numbness Unspecified numbness Cole et al (2020) 21% Ahmed et al (2020) 73% Asher et al (2019) 37% Cui et al (2015) 52% Chiu and Pang (2017) 100% Kim et al (2007) 42% Dong et al (2018) 100%

(continued)

Table 4. (continued)

Clinical Symptom	Sensitivity	Clinical Symptom	Sensitivity
Tetreault et al (2015)	89%	Du et al (2013)	51%
		Kong et al (2019)	88%
Wang et al (2012)	53%	Rajasekaran et al (2016)	57%
Wei et al (2019)	87%	Raslan et al (2014)	62%
Great toe numbness		Trunk numbness	
		Cui et al (2015)	4%
Cui et al (2015)	4%	Zhang et al (2018)	5%
Jnspecified upper extremity sensory	.,.	Unspecified lower extremity sensory	
symptoms		symptoms	
symptoms		Chibbaro et al (2009)	40%
Chibbaro et al (2009)	78%	Holly et al (2009)	29%
	75%	Kim et al (2018)	25%
Kim et al (2018)			OS: 17%
Niu et al (2020)	CC: 46%, OS: 71%	Niu et al (2020)	03. 17%
Jnspecified hand sensory symptoms		Sensory radicular symptoms	1000
(numbness or paresthesias)	100/	Jain et al (2009)	100%
Holly et al (2009)	48%		
Holly et al (2017)	44%		
Hossam et al (2013)	100%		
land paresthesias		Upper extremity paresthesia	
Choi and Kim (2018)	24%	Choi and Kim (2018)	29%
		Tetreault et al (2015)	57%
Moussellard et al (2014)	93%	Vitzthum and Dalitz (2009)	70%
(Wei et al (2019)	54%
		Williams et al (2009)	67%
ower extremity paresthesia		Unspecified paresthesias	
		Chacko et al (2012)	86%
Williams et al (2009)	58%	Chacko et al (2014)	85%
		Kim et al (2010)	92%
		Turel et al (2013)	86%
ensory change or disturbance		Tightness of the trunk or legs	
Burkhardt et al (2017)	78%	Hossam et al (2013)	53%
· · ·	53%	· · · · · · · · · · · · · · · · · · ·	
Kang et al (2020)			
Kim et al (2010)	36%		
Scholler et al (2020)	90%		
Zonesthesia/Band-like sensation at		Heaviness	
chest or trunk			
Dong et al (2018)	100%	Ahmed et al (2020)	83%
Wang et al (2012)	38%		
Zhang et al (2018)	20%		
Dther			
Dyskinesia		Respiratory difficulty	
Kang et al (2020)	37%	Chatley et al (2009)	2%
	5770	Moussellard et al (2014)	0%
.'hermitte phenomenon		Knee buckling	•
Chatley et al (2009)	2%	Kiris and Kilincer (2008)	88%
Hossam et al (2013)	77%		
Tetreault et al (2015)	27%		
Wei et al (2019)	19%		
Giddiness		Dizziness	
Williams et al (2009)	8%	Audat et al (2018)	54%
		Sugawara et al (2009)	95%; vertigo: 10%, disequilibrium: 29%, presyncope: 0%; light-headedness: 86%
tiffness			P/F, "8.10 100000000 00/
	80%		
Chatley et al (2009)			
Hossam et al (2013)	60%		
Lo (2007)	Leg: 61%		

Gait Dysfunction.						
Study	TP	FP		ΤN	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	1622	0	631	0	0.72 [0.70, 0.74]	•
Burkhardt 2017	20	0	3	0	0.87 [0.66, 0.97]	
Chatley 2009	55	0	9	0	0.86 [0.75, 0.93]	
Chibbaro 2009	205	0	63	0	0.76 [0.71, 0.81]	
Choi and Kim 2018	2	0	15	0	0.12 [0.01, 0.36]	
Cook 2009	10	0	8	0	0.56 [0.31, 0.78]	
Cui 2015	8	0	15	0	0.35 [0.16, 0.57]	
Dong 2018	60	0	0	0	1.00 [0.94, 1.00]	-
Du 2013	56	0	42	0	0.57 [0.47, 0.67]	
Holly 2009	16	0	5	0	0.76 [0.53, 0.92]	
Holly 2017	11	0	5	0	0.69 [0.41, 0.89]	
Hossam 2013	30	0	0	0	1.00 [0.88, 1.00]	-
Hou 2020	8	0	7	0	0.53 [0.27, 0.79]	
Kim 2007	20	0	6	0	0.77 [0.56, 0.91]	
Kong 2019	8	0	24	0	0.25 [0.11, 0.43]	
Konya 2009	4	0	36	0	0.10 [0.03, 0.24]	
Moussellard 2014	53	0	14	0	0.79 [0.67, 0.88]	
Tetreault 2015	568	0	174	0	0.77 [0.73, 0.80]	
Turel 2013	28	0	0	0	1.00 [0.88, 1.00]	_
Vitzthum and Dalitz 2007		0	6	0	0.86 [0.72, 0.95]	
Wei 2019	49	0	40	0	0.55 [0.44, 0.66]	
Williams 2009	20	0	4	0	0.83 [0.63, 0.95]	
Zhang 2018	331	0	129	0	0.72 [0.68, 0.76]	
Zhou 2015	13	0	18	0	0.42 [0.25, 0.61]	
Zhou 2018	10	0	8	0	0.56 [0.31, 0.78]	
Difficulty Climbing.						0 0.2 0.4 0.0 0.8 1
Study TP FP	FN TN	Ser	nsitivi	ty (9	5% CI)	Sensitivity (95% CI)
Thakar 2009 49 0	21 0		0.70 [0.58,	0.80]	
Walking Fatigue.						0 0.2 0.4 0.6 0.8 1
Study TP FP	FN TN	Sens	sitivit	v (95	% CI)	Sensitivity (95% CI)
	27 0		.40 [0			
Imbalance.						0 0.2 0.4 0.6 0.8 1
Study	TP FP	FN .	TN :	Sensi	itivity (95% CI)	Sensitivity (95% CI)
*Weighted Average 1	18 0 3	98	0		23 [0.19, 0.27]	-
Cole 2020		29	0		12 [0.03, 0.28]	
Cui 2015		22	0		04 [0.00, 0.22]	
	13 0 3		0		25 [0.21, 0.29]	· · · · · · · · · · · · · · · · · · ·

Figure 3. Frequency of gait impairment and imbalance in degenerative cervical myelopathy.

Study	ΤР	FP	FN	TN	I S	ensitiv	vity (95% CI)
Weighted Average	280	0	442	C)	0.39	[0.35, 0.42]
udat 2018	133	0	6	C)	0.96	[0.91, 0.98]
Chacko 2012	15	0	94	C)	0.14	[0.08, 0.22]
Chacko 2014	23	0	130	C)	0.15	[0.10, 0.22]
Chatley 2009	17	0	47	C)	0.27	[0.16, 0.39]
Cole 2020	3	0	30	C)	0.09	[0.02, 0.24]
I-Ghandour 2020	33	0	32	C)	0.51	[0.38, 0.63]
(im 2007	9	0	17	C)		[0.17, 0.56]
Kiris and Kilincer 2008	8	0	32	C)		[0.09, 0.36]
Raslan 2014	8	0	13	C)		[0.18, 0.62]
Scholler 2020	10	0	10	C)		[0.27, 0.73]
urel 2013	2	0	26)		[0.01, 0.24]
Villiams 2009	19	0	5)		[0.58, 0.93]
leck and/ or Shoulder	Pain.						
study		т	ΡF	P	FN	TN	Sensitivity (95% CI)
		139					
Weighted Average					1351	0	0.51 [0.49, 0.53]
udat 2018		13		0	3		0.98 [0.94, 1.00]
Burkhardt 2017				0	4		0.83 [0.61, 0.95]
Chatley 2009				0	39		0.39 [0.27, 0.52]
Cheung 2018		4		0	15		0.76 [0.64, 0.86]
Choi and Kim 2018				0	13		0.24 [0.07, 0.50]
Cole 2020				0	22		0.33 [0.18, 0.52]
Cook 2009		1		0	1		0.94 [0.73, 1.00]
Cui 2015				0	21	0	0.09 [0.01, 0.28]
)ong 2018				0	0		1.00 [0.94, 1.00]
I-Ghandour 2020				0	16		0.75 [0.63, 0.85]
Sembruch 2019		16		0	247		0.40 [0.35, 0.45]
Serling 2017		10		0	99		0.51 [0.44, 0.58]
ain 2009				0	0		1.00 [0.88, 1.00]
(im 2010		1	8	0	18		0.50 [0.33, 0.67]
(im 2018			6	0	26	0	0.19 [0.07, 0.36]
Kiris and Kilincer 2008		1	15	0	25	0	0.38 [0.23, 0.54]
long 2019		3	32	0	0	0	1.00 [0.89, 1.00]
Konya 2009		3	36	0	4	0	0.90 [0.76, 0.97]
au 2017		9	96	0	49	0	0.66 [0.58, 0.74]
o 2007		1	6	0	30	0	0.35 [0.21, 0.50]
loussellard 2014		3	35	0	32		0.52 [0.40, 0.65]
liu 2020		26		0	216		0.55 [0.51, 0.60]
Scholler 2020				0	5		0.75 [0.51, 0.91]
hakar 2009				0	39		0.44 [0.32, 0.57]
hakar and Rajshekhar 2	2012			0	29		0.43 [0.29, 0.58]
Villiams 2009				0	11		0.54 [0.33, 0.74]
hang 2018				0	363		0.21 [0.17, 0.25]
2015				0	19		0.39 [0.22, 0.58]
hou 2018				0	5		0.72 [0.47, 0.90]
Ipper Limb Pain.							
itudy		TF	• FP	, ,	FN 1	TN S	ensitivity (95% CI)
		450			96	0	
Maightad Avarage		450					0.43 [0.40, 0.46]
Weighted Average		1) ()	1	98	0	0.26 [0.21, 0.32]
hibbaro 2009					40	0	0 45 10 00 0 501
Chibbaro 2009 Gerling 2017		91			12	0	0.45 [0.38, 0.52]
Chibbaro 2009 Gerling 2017 Konya 2009		91	4 0)	36	0	0.10 [0.03, 0.24]
Chibbaro 2009 Gerling 2017		91	4 0 9 0) 2			




Figure 4. Frequency of pain symptoms in degenerative cervical myelopathy.

Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average 132 0 192 0 0.41 [0.35, 0.46]	+
Cho 2010 31 0 0 0 1.00 [0.89, 1.00]	-
Hossam 2013 26 0 4 0 0.87 [0.69, 0.96]	
Kato 2008 27 0 118 0 0.19 [0.13, 0.26]	-
Thakar and Rajshekhar 2012 12 0 39 0 0.24 [0.13, 0.37]	
Zhang 2020 36 0 31 0 0.54 [0.41, 0.66]	
Back Pain.	0 0.2 0.4 0.6 0.8
Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI
*Weighted Average 31 0 128 0 0.19 [0.14, 0.27]	-
Cole 2020 3 0 30 0 0.09 [0.02, 0.24]	
Kawakita 2009 28 0 98 0 0.22 [0.15, 0.30]	
Lower Limb Pain.	0 0.2 0.4 0.6 0.8
Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI
Konya 2009 4 0 36 0 0.10 [0.03, 0.24]	
Unspecified Pain.	0 0.2 0.4 0.6 0.8
Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% Cl
*Weighted Average 46 0 69 0 0.40 [0.31, 0.50]	
Chiu and Pang 2017 17 0 55 0 0.24 [0.14, 0.35]	
Vitzthum and Dalitz 2007 29 0 14 0 0.67 [0.51, 0.81]	
	0 0.2 0.4 0.6 0.8
Fundicular Pain.	
Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% C
Chatley 2009 3 0 61 0 0.05 [0.01, 0.13]	—
Headache.	0 0.2 0.4 0.6 0.8
Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% C
Williams 2009 2 0 22 0 0.08 [0.01, 0.27]	0 0.2 0.4 0.6 0.8
Chest/ Abdominal Discomfort.	
Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% C
Kim 2007 15 0 11 0 0.58 [0.37, 0.77]	
Spasm.	0 0.2 0.4 0.0 0.0
Study TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% C
Konya 2009 36 0 4 0 0.90 [0.76, 0.97]	
	0 0.2 0.4 0.6 0.8

Figure 4. Continued.

57%-65%).^{30,54,64,67,71} In a single study by Williams et al⁶⁷ (2009), 58% of patients reported lower extremity paresthesias. Finally, rates of any lower extremity sensory symptom were lower than rates of any upper sensory symptom and ranged from 17% to 40% (weighted average: 25%, 95% CI 22%-29%).^{26,39,47,57}

Based on two studies, a minority of patients complained of great toe (4%) and trunk numbness (4%-5%).^{30,71} Rates of zonesthesia (ie band-like sensation at chest or trunk) ranged from 20% to 100% across three studies.^{32,69,71} Finally, 53% of patients experienced tightness of trunk or legs and 83% reported heaviness.^{21,40} Rates of unspecified numbness varied from 37% to 100% across eight studies (weighted average:

60%, 95% CI 56%-64%),^{21,22,29,32,33,51,58,59} while rates of unspecified paresthesias ranged from 82% to 92% across four studies (weighted average: 86%, 95% CI 82%-90%).^{24,46,66,75}

Symptoms Related to Autonomic Function. Twenty-eight studies reported the frequency of bladder and/or bowel dys-function in patients with DCM.^{20,21,23-26,34,38-40,42,43,46-48,50}, ^{54-57,59-62,66,67,71,75} In a study by Misawa et al⁵⁵ (2008), patients were asked about subjective urinary symptoms and were required to complete a three day voiding diary. Based on their results, 16 (68%) patients reported difficulty urinating, 10 (48%) felt as though they had residual urine, five (24%) experienced

Hand Clumsiness.					
Study	TP FF	FN	ΤN	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	942 0		0	0.69 [0.67, 0.72]	_
Chatley 2009	47 C		0	0.73 [0.61, 0.84]	
Chibbaro 2009	150 C	118	0	0.56 [0.50, 0.62]	-
Choi and Kim 2018	8 C	9	0	0.47 [0.23, 0.72]	
Cui 2015	6 0	17	0	0.26 [0.10, 0.48]	
Hossam 2013	27 C		0	0.90 [0.73, 0.98]	
Hou 2020	10 C		0	0.67 [0.38, 0.88]	
Lo 2007	33 C		0	0.72 [0.57, 0.84]	
Tetreault 2015	556 C		0	0.75 [0.72, 0.78]	
Thakar 2009	56 0		0	0.80 [0.69, 0.89]	
Wei 2019	49 C	40	0	0.55 [0.44, 0.66]	0 0.2 0.4 0.6 0.8 1
Loss of Hand Functi	on/ Fine	Notor	Distu	irbance.	0 0.2 0.4 0.8 0.8 1
Study	TP FF	FN	TN	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	170 C	414	0	0.29 [0.25, 0.33]	
Cook 2009	13 0	5	0	0.72 [0.47, 0.90]	
Holly 2009	15 C	6	0	0.71 [0.48, 0.89]	
Holly 2017	10 C		0	0.63 [0.35, 0.85]	
Wang 2012	24 C		0	0.53 [0.38, 0.68]	
Williams 2009	8 C		0	0.33 [0.16, 0.55]	
Zhang 2018	100 C	360	0	0.22 [0.18, 0.26]	
Any Hand Symptom	s.				0 0.2 0.4 0.6 0.8 1
Study TP FP	FN TN	Sens	sitivi	ty (95% CI)	Sensitivity (95% CI)
Cole 2020 28 0	5 0	C	.85 [0.68, 0.95]	
	-				0 0.2 0.4 0.6 0.8 1
Any Upper Extremity	y Sympto	m.			
Study	TP FP	FN 1	N	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	32 0	17	0	0.65 [0.50, 0.78]	
Zhou 2015	21 0	10	0	0.68 [0.49, 0.83]	
Zhou 2018	11 0	7	0	0.61 [0.36, 0.83]	
				5 - 6 - 161	0 0.2 0.4 0.6 0.8 1
Difficulty Eating.					
Study TP	FP FN 1	'N Se	ensiti	vity (95% CI)	Sensitivity (95% CI)
Thakar 2009 38	0 32	0	0.5	4 [0.42, 0.66]	
		10.000			0 0.2 0.4 0.6 0.8 1
Unspecified Fine Mo	otor Diffic	ulties.			
Study TP	FP FN	TN S	ensi	tivity (95% CI)	Sensitivity (95% CI)
Gerling 2017 57	0 146	0		28 [0.22, 0.35]	
					0 0.2 0.4 0.6 0.8 1
Hand Weakness.					
Study	TP FP	FN 1	N	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	4 0	36	0	0.10 [0.03, 0.24]	- -
Choi and Kim 2018	3 0	14	0	0.18 [0.04, 0.43]	
Cui 2015	1 0	22	0	0.04 [0.00, 0.22]	
				8	0 0.2 0.4 0.6 0.8 1
Foot Weakness.					
Study TP F	PFNT	N Se	nsiti	vity (95% CI)	Sensitivity (95% CI)
Konya 2009 4		0		[0.03, 0.24]	
		1			0 0.2 0.4 0.6 0.8 1

Figure 5. Frequency of motor symptoms in degenerative cervical myelopathy.

Upper Extremity Clumsiness. TP FP FN TN Sensitivity (95% CI) Study Sensitivity (95% CI) Cui 2015 1 0 22 0 0.04 [0.00, 0.22] 0.2 0.4 0.6 0.8 1 Lower Extremity Clumsiness. Study TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Cui 2015 0 22 0.04 [0.00, 0.22] 1 0 0.2 0.4 0.6 0.8 1 0 Upper Extremity Weakness. Study TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) *Weighted Average 897 0 657 0 0.58 [0.55, 0.60] Ahmed 2020 26 0 0 0.87 [0.69, 0.96] 4 Chatley 2009 10 0 54 0 0.16 [0.08, 0.27] Chibbaro 2009 178 0 90 0 0.66 [0.60, 0.72] Choi and Kim 2018 8 0 9 0 0.47 [0.23, 0.72] Cole 2020 0.12 [0.03, 0.28] 4 0 29 0 Cui 2015 0 22 0 0.04 [0.00, 0.22] 1 Du 2013 57 0 41 0 0.58 [0.48, 0.68] Kim 2018 0 26 6 0 0.19 [0.07, 0.36] Niu 2020 400 0 84 0 0.83 [0.79, 0.86] Raslan 2014 9 0 12 0 0.43 [0.22, 0.66] 22 0 0.92 [0.73, 0.99] Williams 2009 2 0 Zhang 2018 176 0 284 0 0.38 [0.34, 0.43] 0.2 0.4 0.6 0.8 1 Lower Extremity Weakness. Sensitivity (95% CI) Sensitivity (95% CI) Study TP FP FN TN *Weighted Average 688 0 588 0 0.54 [0.51, 0.57] Ahmed 2020 19 0 0 0.63 [0.44, 0.80] 11 0.03 [0.00, 0.11] Chatley 2009 2 0 62 0 Cui 2015 0 22 0 0.04 [0.00, 0.22] 1 Du 2013 28 0 70 0 0.29 [0.20, 0.39] Kim 2018 0.41 [0.24, 0.59] 13 0 19 0 Konya 2009 4 0 36 0 0.10 [0.03, 0.24] Niu 2020 393 0 91 0 0.81 [0.77, 0.85] Raslan 2014 7 0 14 0 0.33 [0.15, 0.57] Williams 2009 0.88 [0.68, 0.97] 21 0 3 0 Zhang 2018 200 0 260 0 0.43 [0.39, 0.48] 0.2 0.4 0.6 0.8 Weakness. Study TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) *Weighted Average 1024 0 349 0 0.75 [0.72, 0.77] Asher 2019 0 110 0.55 [0.49, 0.61] 135 0 Burkhardt 2017 0 10 0 0.57 [0.34, 0.77] 13 Chatley 2009 50 0 14 0 0.78 [0.66, 0.87] El-Ghandour 2020 59 0 6 0 0.91 [0.81, 0.97] Kommu 2014 61 0 2 0 0.97 [0.89, 1.00] Kong 2019 16 0 16 0 0.50 [0.32, 0.68] Rajasekaran 2016 7 0 23 0 0.23 [0.10, 0.42] Scholler 2020 17 0.15 [0.03, 0.38] 3 0 0 0 Tetreault 2015 615 0 127 0.83 [0.80, 0.86] Wei 2019 0 24 0 0.73 [0.63, 0.82] 65 0 0.2 0.4 0.6 0.8

Figure 5. Continued.

urgency and one (5%) lacked a desire to void. Based on the three day voiding diary, two patients had urinary retention, four experienced nocturia, one had oliguria and four had episodes of urge incontinence. Across several studies, the sensitivities of bladder dysfunction for diagnosis DCM ranged from 4% to 68% with a weighted average of 38% (95% CI 34%-43%). Other studies did not distinguish between bladder and bowel dysfunction and either reported the frequency of sphincter disturbance $(7\%-100\%)^{21,40,48,50,54,57,59}$ or of bladder and/or bowel dysfunction (5%-30%).^{20,26,38,39,42,43,61,62,71}

Study	TP	FP	EN	TN	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	503	0		0	0.69 [0.66, 0.72]	
Chiu and Pang 2017 Choi and Kim 2018	32 1	0	40 16	0	0.44 [0.33, 0.57]	
		0	22	0	0.06 [0.00, 0.29]	-
Cui 2015	1 24	0	16	0	0.04 [0.00, 0.22]	
Konya 2009 Lo 2007	38	0	8		0.60 [0.43, 0.75]	
Thakar 2009	50 67	0	3	-	0.83 [0.69, 0.92] 0.96 [0.88, 0.99]	_
Zhang 2018	340		120	0	0.74 [0.70, 0.78]	
			120	0	0.74 [0.70, 0.78]	0 0.2 0.4 0.6 0.8 1
Lower Extremity Nu	mbnes	s.				
Study		FP	FN		Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	382		241	0	0.61 [0.57, 0.65]	
Cui 2015	4	0	19	0	0.17 [0.05, 0.39]	
Lo 2007	30	0	16	0	0.65 [0.50, 0.79]	
Thakar 2009	64	0	6	0	0.91 [0.82, 0.97]	
Williams 2009	20	0	4	0	0.83 [0.63, 0.95]	
Zhang 2018	264	0	196	0	0.57 [0.53, 0.62]	0 0.2 0.4 0.6 0.8 1
Hand Numbness.						
Study		FP	FN		Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	805		171	0	0.82 [0.80, 0.85]	
Cole 2020	7	0	26	0	0.21 [0.09, 0.39]	
Cook 2009	10	0	8	0	0.56 [0.31, 0.78]	
Cui 2015	12	0	11	0	0.52 [0.31, 0.73]	
Kim 2007	11	0	15	0	0.42 [0.23, 0.63]	
Tetreault 2015	664	0	78	0	0.89 [0.87, 0.92]	
Wang 2012	24	0	21	0	0.53 [0.38, 0.68]	
Wei 2019	77	0	12	0	0.87 [0.78, 0.93]	0 0.2 0.4 0.6 0.8 1
Unspecified Numbro	ess.					
Study	TP	FP	FN	TN	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	353	0	235	0	0.60 [0.56, 0.64]	-
Ahmed 2020	22	0	8	0	0.73 [0.54, 0.88]	
Asher 2019	91	0	154	0	0.37 [0.31, 0.44]	-
Chiu and Pang 2017	72	0	0	0	1.00 [0.95, 1.00]	-
Dong 2018	60	0	0	0	1.00 [0.94, 1.00]	-
Du 2013	50	0	48	0	0.51 [0.41, 0.61]	
Kong 2019	28	0	4	0	0.88 [0.71, 0.96]	
Rajasekaran 2016	17	0	13	0	0.57 [0.37, 0.75]	
Raslan 2014	13	0	8	0	0.62 [0.38, 0.82]	
Great Toe Numbnes	s.					0 0.2 0.4 0.6 0.8 1
	FN T	N S	Sensi	tivity	(95% CI)	Sensitivity (95% CI)
Cui 2015 1 0	22	0	0.0	04 [0.	00, 0.22]	0 0.2 0.4 0.6 0.8 1
Trunk Numbness.						0 0.2 0.4 0.0 0.8 1
Study	TP F	FP	FN .	ΓN	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	22	0 4	161	0	0.05 [0.03, 0.07]	
Cui 2015	1	0	22	0	0.04 [0.00, 0.22]	-
Zhang 2018	21	0 4	139	0	0.05 [0.03, 0.07]	
Unspecified Upper E	xtremi	ity Se	enso	ry Sy	mptoms.	0 0.2 0.4 0.6 0.8 1
Study	ΤР	FP	FN	TN	Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	577	0	207	0	0.74 [0.70, 0.77]	-
Chibbaro 2009	210	0	58	0	0.78 [0.73, 0.83]	-
Kim 2018	24	0	8	0	0.75 [0.57, 0.89]	
Niu 2020	343		141	0	0.71 [0.67, 0.75]	<u> </u>
Unspecified Lower E						0 0.2 0.4 0.6 0.8
						Densitie the Internation
Study	TP		FN		Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	205		600	0	0.25 [0.22, 0.29]	•
Chibbaro 2009	107		161	0	0.40 [0.34, 0.46]	
	6	0	15	0	0.29 [0.11, 0.52]	
Holly 2009						
Holly 2009 Kim 2018	8	0	24	0	0.25 [0.11, 0.43]	-
Holly 2009		0				0 0.2 0.4 0.6 0.8

Figure 6. Frequency of sensory symptoms in degenerative cervical myelopathy.

Unspecified Hand Sensory Symptoms (Numbness or Paresthesias). TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study 0.65 [0.56, 0.74] *Weighted Average 73 0 39 0 Cook 2009 0 0.58 [0.42, 0.72] 26 19 0 Holly 2009 10 0 11 0 0.48 [0.26, 0.70] Holly 2017 7 0 9 0 0.44 [0.20, 0.70] 0 0 1.00 [0.88, 1.00] Hossam 2013 30 0 0 0.2 0.4 0.6 0.8 1 Sensory Radicular Symptoms. TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study Jain 2009 30 0 0 0 1.00 [0.88, 1.00] 0 0.2 0.4 0.6 0.8 1 Hand Paresthesias. Study TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) 0 18 *Weighted Average 66 0 0.79 [0.68, 0.87] 4 0 0 0.24 [0.07, 0.50] Choi and Kim 2018 13 Moussellard 2014 0 0.93 [0.83, 0.98] 62 0 5 0 0.2 0.4 0.6 0.8 1 Upper Extremity Paresthesia FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study TP *Weighted Average 0 394 0 57 [0 54 0 60] 521 0 Choi and Kim 2018 5 0 12 0 0.29 [0.10. 0.56] Tetreault 2015 422 0 320 0 0.57 [0.53, 0.60] Vitzthum and Dalitz 2007 0.70 [0.54, 0.83] 30 0 13 0 Wei 2019 48 0 41 0 0.54 [0.43, 0.65] Williams 2009 16 0 8 0 0.67 [0.45, 0.84] 0 0.2 0.4 0.6 0.8 Lower Extremity Paresthesia. TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study Williams 2009 14 0 10 0 0.58 [0.37, 0.78] 0 0.2 0.4 0.6 0.8 1 Unspecified Paresthesias TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study *Weighted Average 281 0 45 0 0.86 [0.82, 0.90] -Chacko 2012 94 0 15 0 0.86 [0.78, 0.92] . Chacko 2014 130 0 23 0 0.85 [0.78, 0.90] . Kim 2010 33 3 0 0 0.92 [0.78, 0.98] Turel 2013 24 4 0 0.86 [0.67, 0.96] 0 0 0.2 0.4 0.6 0.8 Sensory Change or Disturbance. FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study TP FP *Weighted Average 89 0 65 0.58 [0.50, 0.66] 0 Burkhardt 2017 18 0 0 0.78 [0.56, 0.93] 5 Kang 2020 40 0 35 0 0.53 [0.41, 0.65] Kim 2010 0 0 0.36 [0.21, 0.54] 13 23 Scholler 2020 0 2 0 0.90 [0.68, 0.99] 18 0 0.2 0.4 0.6 0.8 Tightness of the Trunk or Legs. TP FP FN TN Sensitivity (95% CI) \$ Sensitivity (95% CI) Study Hossam 2013 16 0 14 0 0.53 [0.34, 0.72] 0 0.2 0.4 0.6 0.8 1 Zonesthesia/Band-Like Sensation at Chest or Trunk. TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study *Weighted Average 170 0 395 0.30 [0.26, 0.34] 0 Dong 2018 0 0 1.00 [0.94, 1.00] 60 0 Wang 2012 17 0 28 0 0.38 [0.24, 0.53] Zhang 2018 93 0 367 0 0.20 [0.17, 0.24] 0 0.2 0.4 0.6 0.8 Heaviness. TP FP FN TN Sensitivity (95% CI) Sensitivity (95% CI) Study Ahmed 2020 25 0 5 0 0.83 [0.65, 0.94] 0 0.2 0.4 0.6 0.8

Figure 6. Continued.

Three studies reported the frequency of sexual dysfunction in a cohort of DCM patients.^{26,37,62} In He et al³⁷ (2006), patients were included in the "sexual dysfunction" group if they reported difficulty in penile erection or ejaculation. Based on their results, approximately 3% of patients undergoing surgery for DCM experienced sexual dysfunction. Of these, the majority (82%) had an abnormal psychogenic erection (ie erection resulting from extrinsic stimuli), while only 18%

Bladder and Bowel Symptoms.										
Study		TP	FP		TN	Sensitivity (95% CI)	Sensitivity (95% CI)			
*Weighted Average		325	0	1438	0	0.18 [0.17, 0.20]				
Ahmed 2020		13	0	17	0	0.43 [0.25, 0.63]				
Audat 2018		23	0	116	0	0.17 [0.11, 0.24]	-			
Chibbaro 2009		36	0	232	0	0.13 [0.10, 0.18]	•			
Holly 2009		2	0	19	0	0.10 [0.01, 0.30]	-			
Holly 2017		2	0	14	0	0.13 [0.02, 0.38]				
Hossam 2013		30	0	0	0	1.00 [0.88, 1.00]				
Jain 2009		9	0	21	0	0.30 [0.15, 0.49]				
Kang 2020		7	0	68	0	0.09 [0.04, 0.18]	-			
Kim 2007		5	0	21	0	0.19 [0.07, 0.39]	-			
Kommu 2014		13	0	50	0	0.21 [0.11, 0.33]				
Lo 2007		3	0	43	0	0.07 [0.01, 0.18]	-			
Niu 2020		80	0	404	0	0.17 [0.13, 0.20]	-			
Raslan 2014		2	0	19	0	0.10 [0.01, 0.30]				
Scholler 2020		1	0	19	0	0.05 [0.00, 0.25]				
Sinha and Jagetia 201	11	4	0	30	0	0.12 [0.03, 0.27]	-			
Zhang 2018		95	0	365	0	0.21 [0.17, 0.25]	. F 1 1 7 7			
Bladder Dysfunction.										
Study	ТР	FP	FI	N TN	Sei	nsitivity (95% CI)	Sensitivity (95% CI)			
*Weighted Average	256	0	420	0 (0.38 [0.34, 0.42]	.			
Burkhardt 2017	1	0	22	2 0		0.04 [0.00, 0.22]	-			
Chacko 2012	36	0	73	3 0		0.33 [0.24, 0.43]				
Chacko 2014	64	0	89	0		0.42 [0.34, 0.50]				
Chatley 2009	27	0	37	7 0		0.42 [0.30, 0.55]				
El-Ghandour 2020	27	0	38	3 0		0.42 [0.29, 0.54]				
Kim 2010	6	0	30	0 (0.17 [0.06, 0.33]				
Kim 2018	4	0	28	3 0		0.13 [0.04, 0.29]				
Misawa 2005	29	0	2	7 0		0.52 [0.38, 0.65]				
Moussellard 2014	39	0	28	3 0		0.58 [0.46, 0.70]				
Revannapa 2017	13	0	6	5 0		0.68 [0.43, 0.87]				
Turel 2013	6					0.21 [0.08, 0.41]				
Williams 2009	4		1 1000	St (2		0.17 [0.05, 0.37]				
Bowel Dysfunction.		Ū				[,]	0 0.2 0.4 0.6 0.8 1			
Study	ΤР	FP	FN	TN	Sene	itivity (95% CI)	Sensitivity (95% CI)			
			75							
*Weighted Average	23	0		0		23 [0.15, 0.33]	-			
Chatley 2009	21	0	43	0		33 [0.22, 0.46]				
Kim 2010	2	0	32	0	0	.06 [0.01, 0.20]				
Sexual Dysfunction.										
Study		TP	FP	FN	ΤN	Sensitivity (95% CI)	Sensitivity (95% CI)			
*Weighted Average		39	0	1016	0	0.04 [0.03, 0.05]				
Chibbaro 2009		15	0	253	0	0.06 [0.03, 0.09]	•			
He 2006		22	0	731	0	0.03 [0.02, 0.04]	•			
Sinha and Jagetia 201	11	2	0	32	0	0.06 [0.01, 0.20]	<u>.</u>			
201		_	-			[]	0 0.2 0.4 0.6 0.8 1			

Figure 7. Frequency of autonomic symptoms in degenerative cervical myelopathy.

demonstrated an abnormal reflexive erection (ie erection elicited by direct penile stimulation). Across three studies, the sensitivity of sexual dysfunction for diagnosing DCM ranged from 3% to 6%.^{26,37,62}

In a study by Sugawara et al (2009), 95% of patients with DCM reported episodes of dizziness, described as vertigo (10%), disequilibrium (29%) or light-headedness (86%). Finally, a minority of patients complained of respiratory difficulties (0%-2%), dyskinesias (37%) or giddiness (8%).^{25,43,56,67}

Other Symptoms. Studies have also reported the frequency of symptoms that do not fall into the above categories.^{6,20,25,40,43,49,54,56,63,67,70} Based on the results of four studies, 2%-77% of patients with DCM experience Lhermitte's phenomena (weighted average: 25%, 95% CI 23%-29%).^{6,25,40,70}

Discussion

This scoping review aimed to summarize the diagnostic accuracy of various symptoms reported in patients with DCM.

Dyskinesia		
Study TP FF	P FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
Kang 2020 28 0	0 47 0 0.37 [0.26, 0.49]	0 0.2 0.4 0.6 0.8 1
Respiratory difficulty	у.	0 0.2 0.4 0.6 0.8 1
Study	TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	1 0 130 0 0.01 [0.00, 0.04]	
Chatley 2009	1 0 63 0 0.02 [0.00, 0.08]	-
Moussellard 2014	0 0 67 0 0.00 [0.00, 0.05]	
L'hermitte Phenome	non	0 0.2 0.4 0.6 0.8 1
Study	TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	239 0 686 0 0.26 [0.23, 0.29]	
Chatley 2009	1 0 63 0 0.02 [0.00, 0.08]	-
Hossam 2013	23 0 7 0 0.77 [0.58, 0.90]	
Tetreault 2015	198 0 544 0 0.27 [0.24, 0.30]	-
Wei 2019	17 0 72 0 0.19 [0.12, 0.29]	
Knee Buckling.		0 0.2 0.4 0.6 0.8 1
Study	TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
Kiris and Kilincer 2008	8 35 0 5 0 0.88 [0.73, 0.96]	
Giddiness.		0 0.2 0.4 0.6 0.8 1
Study TP	FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
Williams 2009 2	0 22 0 0.08 [0.01, 0.27]	
Dizziness.		0 0.2 0.4 0.6 0.8 1
Study	TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	95 0 65 0 0.59 [0.51, 0.67]	- - -
Audat 2018	75 0 64 0 0.54 [0.45, 0.62]	-
Sagawara 2009	20 0 1 0 0.95 [0.76, 1.00]	
	anne an a' dan sharart batasart satasart -	0 0.2 0.4 0.6 0.8 1
Stiffness.		
Study	TP FP FN TN Sensitivity (95% CI)	Sensitivity (95% CI)
*Weighted Average	97 0 43 0 0.69 [0.61, 0.77]	
Chatley 2009	51 0 13 0 0.80 [0.68, 0.89]	
Hossam 2013	18 0 12 0 0.60 [0.41, 0.77]	
Lo 2007	28 0 18 0 0.61 [0.45, 0.75]	
		0 0.2 0.4 0.6 0.8 1

Figure 8. Frequency of other symptoms reported by patients with degenerative cervical myelopathy.

Unfortunately, there is a paucity of studies that compared the frequency of various symptoms between patients with confirmed cervical myelopathy and a control group. Furthermore, the control group in the three studies that met inclusion criteria for KQ1 was either not well defined or was based on the absence of certain imaging findings (eg cord compression, hyperintensity on T2-weighted images). It may be difficult to distinguish patients with DCM from those without using MRI characteristics due to poor correlation between imaging findings and disease severity.⁷⁷ Based on the results of these three studies, the presence of neck pain is moderately to highly sensitive for diagnosing DCM, but not specific. While these findings carry face validity, many of the other results from KQ1 do not. For example, stand-alone findings of tremor, cervical vertigo, jitteriness and apraxia are probably not specific for DCM as they can be present in a wide range of neurologic disorders, including Parkinson's disease, stroke, vestibular dysfunction and cerebellar pathology. It is important to note that the presented results for sensitivity and specificity in this review are extracted from studies that are screening a particular population (and not just a random group of individuals).

Symptoms Related to Gait

Patients with DCM may experience gait instability, walking fatigue or difficulty climbing up or down the stairs. The proportion of individuals with gait dysfunction ranged from 10% to 100%. It is postulated that gait impairment in DCM is a result of both upper motor neuron and proprioceptive dysfunction as well as damage to the rubrospinal, vestibulospinal and reticulospinal tracts.78,79 Patients with early DCM will often have subtle instability and difficulty maintaining posture whereas those with more severe disease also have a component of weakness and spasticity that contributes to gait impairment. Several studies have analyzed various gait parameters and have identified that patients with DCM tend to walk slower, have difficulties generating adequate stride length, and spend less time in single support.⁸⁰⁻⁸⁴ While not captured in this scoping review, DCM must also be considered in patients with recurrent falls.⁸⁵ Notably, many elderly patients with DCM may consider gait instability as a natural part of aging and therefore may not report it when asked about symptoms. Therefore, history taking should critically evaluate if gait disturbance developed in conjuncture with other myelopathy-related symptoms. Furthermore, some older patients may not be aware of their gait impairment due to frailty and reduced mobility from other medical conditions (eg, degenerative and inflammatory joint disease, peripheral neuropathy, nutrient deficiency). As such, a thorough physical examination including gait assessments is essential when evaluating an individual for potential DCM.

Symptoms Related to Pain

Patients with DCM can present with neck, shoulder, axial, radicular, or diffuse neuropathic pain. Axial or neck pain arises from changes in the musculoskeletal structures including the paraspinal muscles, ligaments or vertebral bodies, whereas radicular pain is secondary to irritation of the nerve roots as they exit the spinal canal. Presence of pain and stiffness can significantly affect a patient's quality of life, disturb sleep and limit ability to perform activities.⁸⁶ Based on this scoping review, neck and/or shoulder pain was the most frequent type of pain, followed by upper extremity pain and axial pain. Of note, this review intended to exclude patients with cervical radiculopathy (unless used as a control group to explore other symptoms) or myeloradiculopathy; as such, the incidence of radiating pain is potentially even higher than reported. Finally, back and lower extremity pain are not common symptoms of DCM and may only be present if a patient has concomitant lumbar arthritis and stenosis. Not surprisingly, neck pain is not specific for DCM. In fact, approximately 30%-50% of adults will experience neck pain in any given year.⁸⁷ In addition, a primary care practitioner will, on average, assess seven patients per week with neck or upper extremity symptoms.⁸⁸ It is advised that patients with complaints of neck pain be questioned and examined for evidence of myelopathy.

Symptoms Related to Hand and Upper and Lower Extremity Motor Function

Hand symptoms are common in patients with DCM, including clumsiness, loss of dexterity and weakness. In fact, 85% of patients with DCM may exhibit at least one symptom

involving their hands.³¹ Based on the results of this scoping review, hand clumsiness is typically present in 69% of patients with DCM. Individuals with DCM will often report difficulties manipulating small objects such as buttons or screws, using utensils to eat or typing on a keyboard.^{38,39,64} Furthermore. patients may also complain that they often drop objects. Hand dysfunction in patients with DCM is due to a combination of increased stretch reflexes and worsening proprioceptive function from underlying injury of the corticospinal tracts and dorsal columns.⁸⁹ A detailed examination of the hand may unveil finger extensor and abductor weakness, inability to grip and release and loss of proprioception.⁹⁰ Upper and lower extremity motor dysfunction may also be present in patients with DCM; however, the weighted averages are less than that of hand clumsiness. In patients with otherwise unspecific symptoms, fine motor dysfunction should be considered a characteristic symptom in DCM.

Symptoms Related to Hand and Upper and Lower Extremity Sensory Function

Patients may complain of sensory disturbances including numbness or paresthesias of their hands and upper or lower extremities. Based on the results of this scoping review, there is no classical pattern or distribution of sensory symptoms in DCM. The weighted averages range from 60% to 82% for hand, upper extremity and lower extremity numbness and from 57% to 79% for similarly distributed paresthesias. Although patients often experience bilateral sensory symptoms due to extrinsic compression of the cord, DCM should not be ruled out in individuals with unilateral symptoms. Importantly, DCM is often misdiagnosed as carpal tunnel syndrome due to overlapping symptoms including paresthesias, hand wasting and loss of dexterity. Furthermore, as DCM, carpal tunnel syndrome is often present bilaterally with one side that might dominate.⁹¹ Patients with suspected carpal tunnel syndrome must be asked targeted questions about other symptoms consistent with myelopathy as well as examined for corticospinal and sensory tract dysfunction. A coexistence of DCM and carpal tunnel syndrome is also possible. Thus, further electrodiagnostic evaluation might be critical in these patients.

Symptoms Related to Autonomic Function

Patients with DCM may report bladder, bowel or sexual dysfunction. A lesion in the cervical spinal cord sometimes manifests as a spastic bladder with symptoms of increased urinary frequency and incontinence due to detrusor-sphincter dyssynergia and impaired feedback from the pontine micturition center.⁹² Furthermore, according to Misawa et al⁵⁵ (2008), patients with DCM had a variety of urinary symptoms, including difficulty urinating and inability to completely empty the bladder. Of the studies that separately reported on

bowel dysfunction, the frequency of difficulties with defecation in patients with DCM was low (6%-33%) compared to urinary complaints (4%-68%). Finally, patients with DCM rarely complained of sexual dysfunction (3%-6%).^{26,37,62} In general, sexual dysfunction is often underreported by patients due to embarrassment or because of the perception that difficulties maintaining an erection or achieving an orgasm are natural parts of aging.93 Furthermore, all of the included studies emphasized male sexual health and none reported the impact of DCM on female sexual function. Of note, patients with DCM were more likely to have an intact reflexogenic erection, thought to originate from the sacral segments of the spinal cord, than an intact psychogenic erection which arises from the cerebrum and is modulated through the thoracic and lumbar segments.³⁷ Other studies have confirmed that patients with complete upper motor neuron lesions experience difficulties obtaining a psychogenic compared to a reflexogenic erection.⁹⁴ It is critical that specific questions be asked about bladder, bowel and sexual function in patients suspected to have DCM as these symptoms may be underreported.

Clinical Implications and Future Directions

When evaluating an individual with suspected DCM, it is important to specifically ask about hand function and fine motor skills (eg tying up buttons, using a screwdriver, doing up jewellery), gait instability, falls, sensory symptoms (eg numbness or paresthesias), neck, shoulder or arm pain, and bladder, bowel or sexual dysfunction. Some patients with DCM will have a dominant and disabling symptom and may fail to report other issues unless directly asked. The presence of symptoms with moderate to high sensitivity for identifying DCM should trigger a clinician to order further neuroimaging to either confirm or rule out this diagnosis. This review also emphasizes that DCM may initially present with subtle, vague or unusual symptoms, indicating that physicians must carry a high degree of clinical suspicion to ensure that DCM is not missed.

This scoping review serves as a first step in identifying the symptoms that should be included in diagnostic criteria for DCM. This will allow clinicians, notably primary care physicians, to better identify DCM, pursue timely neuroimaging and not miss a diagnosis of DCM when it presents in an uncommon way. If patients with DCM can be detected earlier, then they can be referred to specialists with expertise in the treatment of this condition. Ongoing studies have indicated that timely diagnosis and management of DCM results in superior neurological and functional recovery as well as reduces unemployment, dependency on others and healthcare costs.

While this is the first review to summarize current evidence on symptoms in DCM, there are limitations that should be mentioned. First, there were only three studies that included a control group in their analysis; as a result, there is limited information on the specificity of various DCM symptoms. Furthermore, individuals were considered controls if they had cervical spine pain or signs/symptoms of myelopathy but did not have myelomalacia or spinal cord compression on neuroimaging. It is increasingly appreciated that patients can still be diagnosed with DCM in the absence of signal change or even spinal cord compression on static MRI; as such, these control groups may be suboptimal for assessing the accuracy of various symptoms. Second, values for sensitivity and specificity are extracted from studies that are screening a particular population and not just a random group of individuals. Further investigation is required to better calculate sensitivity and specificity of various symptoms using adequate control groups. Nonetheless, this review provides invaluable information on some of the most common symptoms of DCM and will undoubtedly improve understanding of this condition.

Conclusion

Patients with DCM can present with a wide variety of symptoms in their upper and lower extremities, making it difficult to initially diagnose this condition. Based on the results of this review, the most frequent symptoms in DCM include unspecified paresthesias, hand numbness, clumsiness or paresthesias, weakness and gait impairment. Neck and/or shoulder pain was present in 51% of patients with DCM, whereas a minority had back (19%) or lower extremity pain (10%). With respect to autonomic symptoms, bladder dysfunction was uncommon although more frequent than bowel or sexual impairment. The current scoping review provides a framework to create a diagnostic toolkit for specialists, primary care physicians, and allied health professionals.

Acknowledgments

This research aligns with the AO Spine RECODE-DCM top research priority 'Diagnostic Criteria' selected by people living and working with DCM. For further information on how this process was conducted, why this question was prioritized, and global updates on currently aligned research, please visit aospine.org/recode/diagnostic-criteria. This article, including the broader efforts to establish diagnostic criteria for DCM, is led by the RECODE-DCM Diagnostic Criteria Incubator Group. This was initially launched, with support from AO Spine through the AO Spine Knowledge Forum Spinal Cord Injury, a focused group of international Spinal Cord Injury experts. The oversight and support of the incubator has now transitioned to Myelopathy.org, a global charity focused on DCM.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Benjamin Davies b https://orcid.org/0000-0003-0591-5069 Konstantinos Margetis b https://orcid.org/0000-0002-3715-8093 Andrea Boraschi b https://orcid.org/0000-0002-2908-5234 Oke Righteous Obadaseraye b https://orcid.org/0000-0001-8018-6076

Michael G. Fehlings https://orcid.org/0000-0002-5722-6364 Ratko Yurac https://orcid.org/0000-0003-3603-6294 Elizabeth A. Roberts https://orcid.org/0000-0003-2738-4203 Tanzil Rujeedawa https://orcid.org/0000-0002-7089-1684

References

- Nouri A, Tetreault L, Singh A, Karadimas SK, Fehlings MG. Degenerative cervical myelopathy: Epidemiology, genetics, and pathogenesis. *Spine (Phila Pa 1976)*. 2015;40(12):E675-E693. doi: 10.1097/BRS.00000000000913
- Davies BM, Khan DZ, Barzangi K et al. We choose to call it 'degenerative cervical myelopathy': Findings of AO spine RECODE-DCM, an international and multi-stakeholder partnership to agree a standard unifying term and definition for a disease. *Global Spine J.* 2022:219256822211117. doi: 10.1177/ 21925682221111780
- Waqar M, Wilcock J, Garner J, Davies B, Kotter M. Quantitative analysis of medical students' and physicians' knowledge of degenerative cervical myelopathy. *BMJ Open*. 2020;10(1): e028455. doi: 10.1136/bmjopen-2018-028455
- Tetreault L, Lange SF, Chotai S et al. A systematic review of definitions for neurological complications and disease progression in patients treated surgically for degenerative cervical myelopathy. *Spine (Phila Pa 1976)*. 2019;44(18):1318-1331. doi: 10.1097/BRS.00000000003066
- Hilton B, Tempest-Mitchell J, Davies B, Kotter M. Route to diagnosis of degenerative cervical myelopathy in a UK healthcare system: A retrospective cohort study. *BMJ Open*. 2019;9(5):e027000. doi: 10.1136/bmjopen-2018-027000
- Tetreault L, Kopjar B, Cote P, Arnold P, Fehlings MG. A clinical prediction rule for functional outcomes in patients undergoing surgery for degenerative cervical myelopathy: Analysis of an international prospective multicenter data set of 757 subjects. *J Bone Joint Surg Am.* 2015;97(24):2038-2046. doi: 10.2106/JBJS.O.00189
- Pope DH, Mowforth OD, Davies BM, Kotter MRN. Diagnostic delays lead to greater disability in degenerative cervical myelopathy and represent a health inequality. *Spine (Phila Pa 1976)*. 2020; 45(6):368-377. doi: 10.1097/BRS.00000000003305
- Davies BM, Phillips R, Clarke D et al. Establishing the socioeconomic impact of degenerative cervical myelopathy is fundamental to improving outcomes [AO spine RECODE-DCM research priority number 8]. *Global Spine J.* 2022;12(1_suppl): 122s-129s. doi: 10.1177/21925682211039835
- Tracy JA, Bartleson JD. Cervical spondylotic myelopathy. *Neurol.* 2010;16(3):176-187. doi: 10.1097/NRL.0b013e3181da3a29
- Tetreault L, Kalsi-Ryan S, Benjamin D, et al. Degenerative cervical myelopathy: A practical approach to diagnosis. *Global Spine* J. 2022:21925682211072847. doi: 10.1177/21925682211072847

- Tetreault L, Goldstein CL, Arnold P et al. Degenerative cervical myelopathy: A spectrum of related disorders affecting the aging spine. *Spine Neurosurgery* 2015;77(Suppl 4):S51-S67. doi: 10. 1227/NEU.000000000000951
- Hilton B, Gardner EL, Jiang Z et al. Establishing diagnostic criteria for degenerative cervical myelopathy [AO spine RECODE-DCM research priority number 3]. *Global Spine J*. 2022;12(1_suppl):55S-63S. doi: 10.1177/21925682211030871.
- Davies BM, Khan DZ, Mowforth OD et al. RE-CODE DCM (REsearch objectives and common data elements for degenerative cervical myelopathy): A consensus process to improve research efficiency in DCM, through establishment of a standardized dataset for clinical research and the definition of the research priorities. *Global Spine J.* 2019;9(1 Suppl):65S-76S. doi: 10.1177/2192568219832855
- Tricco AC, Lillie E, Zarin W et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Ann Intern Med.* 2018;169(7):467-473. doi: 10.7326/M18-0850
- Davies BM, Goh S, Yi K, Kuhn I, Kotter MRN. Development and validation of a MEDLINE search filter/hedge for degenerative cervical myelopathy. *BMC Med Res Methodol*. 2018; 18(1):73. doi: 10.1186/s12874-018-0529-3
- Khan MA, Mowforth OD, Kuhn I, Kotter MRN, Davies BM. Development of a validated search filter for Ovid Embase for degenerative cervical myelopathy. *Health Info Libr J.* 2023;40: 181-189. doi: 10.1111/hir.12373
- Hori M, Fukunaga I, Masutani Y et al. New diffusion metrics for spondylotic myelopathy at an early clinical stage. *Eur Radiol.* 2012;22(8):1797-1802. doi: 10.1007/s00330-012-2410-9
- Cheung PWH, Wong CKH, Lau ST, Cheung JPY. Psychometric validation of the adapted traditional Chinese (Hong Kong) version of the Japanese orthopaedic association cervical myelopathy evaluation questionnaire (JOACMEQ). *Spine (Phila Pa 1976)*. 2018;43(4):E242-E249. doi: 10.1097/BRS.00000000002287
- Cook C, Roman M, Stewart KM, Leithe LG, Isaacs R. Reliability and diagnostic accuracy of clinical special tests for myelopathy in patients seen for cervical dysfunction. *J Orthop Sports Phys Ther*. 2009;39(3):172-178. doi: 10.2519/jospt.2009. 2938
- Audat ZA, Fawareh MD, Radydeh AM, et al. Anterior versus posterior approach to treat cervical spondylotic myelopathy, clinical and radiological results with long period of follow-up. *Sage Open Med.* 2018;6:2050312118766199. doi: 10.1177/2050312118766199
- Ahmed OEF, Galal A. Multiple level anterior cervical discectomy and fusion versus posterior laminectomy for the management of multilevel cervical spondylotic myelopathy: clinical and radiological outcome. *Egypt J Neurol Psychiatr Neurosurg*. 2020;56(32):32.
- Asher AL, Devin CJ, Kerezoudis P et al. Comparison of outcomes following anterior vs posterior fusion surgery for patients with degenerative cervical myelopathy: An analysis from quality outcomes database. *Neurosurgery*. 2019;84(4):919-926. doi: 10.1093/neuros/nyy144
- 23. Burkhardt BW, Brielmaier M, Schwerdtfeger K, Sharif S, Oertel JM. Smith-Robinson procedure with and without Caspar plating

as a treatment for cervical spondylotic myelopathy: A 26-year follow-up of 23 patients. *Eur Spine J.* 2017;26(4):1246-1253. doi: 10.1007/s00586-017-4988-8

- Chacko AG, Turel MK, Sarkar S, Prabhu K, Daniel RT. Clinical and radiological outcomes in 153 patients undergoing oblique corpectomy for cervical spondylotic myelopathy. *Br J Neurosurg.* 2014;28(1):49-55. doi: 10.3109/02688697.2013. 815326
- Chatley A, Kumar R, Jain VK, Behari S, Sahu RN. Effect of spinal cord signal intensity changes on clinical outcome after surgery for cervical spondylotic myelopathy. *J Neurosurg Spine*. 2009;11(5):562-567. doi: 10.3171/2009.6.SPINE091
- Chibbaro S, Mirone G, Makiese O, George B. Multilevel oblique corpectomy without fusion in managing cervical myelopathy: Long-term outcome and stability evaluation in 268 patients. *J Neurosurg Spine*. 2009;10(5):458-465. doi: 10.3171/2009.1.SPINE08186
- Cho CB, Chough CK, Oh JY, Park HK, Lee KJ, Rha HK. Axial neck pain after cervical laminoplasty. *J Korean Neurosurg Soc.* 2010;47(2):107-111. doi: 10.3340/jkns.2010.47.2.107
- Choi YA, Kim K. Stenosis and neurologic level discrepancies in cervical spondylotic myelopathy. *Pharm Manag PM R*. 2018; 10(10):1051-1055. doi: 10.1016/j.pmrj.2018.04.003
- Chiu AYY, Pang MYC. Assessment of psychometric properties of various balance assessment tools in persons with cervical spondylotic myelopathy. *J Orthop Sports Phys Ther.* 2017; 47(9):673-682. doi: 10.2519/jospt.2017.7283
- Cui JL, Li X, Chan TY, Mak KC, Luk KD, Hu Y. Quantitative assessment of column-specific degeneration in cervical spondylotic myelopathy based on diffusion tensor tractography. *Eur Spine J.* 2015;24(1):41-47. doi: 10.1007/s00586-014-3522-5
- Cole TS, Almefty KK, Godzik J et al. Functional improvement in hand strength and dexterity after surgical treatment of cervical spondylotic myelopathy: A prospective quantitative study. *J Neurosurg Spine*. 2020;32:907-913. doi: 10.3171/2019.10. SPINE19685
- Dong F, Wu Y, Song P et al. A preliminary study of 3.0-T magnetic resonance diffusion tensor imaging in cervical spondylotic myelopathy. *Eur Spine J.* 2018;27(8):1839-1845. doi: 10.1007/s00586-018-5579-z
- 33. Du W, Wang L, Shen Y, Zhang Y, Ding W, Ren L. Long-term impacts of different posterior operations on curvature, neurological recovery and axial symptoms for multilevel cervical degenerative myelopathy. *Eur Spine J.* 2013;22(7):1594-1602. doi: 10.1007/s00586-013-2741-5
- El-Ghandour NMF, Soliman MAR, Ezzat AAM, Mohsen A, Zein-Elabedin M. The safety and efficacy of anterior versus posterior decompression surgery in degenerative cervical myelopathy: A prospective randomized trial. *J Neurosurg Spine*. 2020;33:288-296. doi: 10.3171/2020.2.SPINE191272
- Gembruch O, Jabbarli R, Rashidi A et al. Degenerative cervical myelopathy in higher-aged patients: How do they benefit from surgery? J Clin Med. 2019;9(1):62. doi: 10.3390/jcm9010062
- 36. Gerling MC, Radcliff K, Isaacs R et al. Two-year results of the prospective spine treatment outcomes study: An analysis of

complication rates, predictors of their development, and effect on patient derived outcomes at 2 years for surgical management of cervical spondylotic myelopathy. *World Neurosurg.* 2017; 106:247-253. doi: 10.1016/j.wneu.2017.06.147

- He S, Hussain N, Zhao J, Fu Q, Hou T. Improvement of sexual function in male patients treated surgically for cervical spondylotic myelopathy. *Spine (Phila Pa 1976)*. 2006;31(1):33-36. doi: 10.1097/01.brs.0000192726.53415.bf
- Holly LT, Ellingson BM, Salamon N. Metabolic imaging using proton magnetic spectroscopy as a predictor of outcome after surgery for cervical spondylotic myelopathy. *Clin Spine Surg.* 2017;30(5):E615-E619. doi: 10.1097/BSD.000000000000248
- Holly LT, Freitas B, McArthur DL, Salamon N. Proton magnetic resonance spectroscopy to evaluate spinal cord axonal injury in cervical spondylotic myelopathy. *J Neurosurg Spine*. 2009; 10(3):194-200. doi: 10.3171/2008.12.SPINE08367
- Hossam MSM, Shabaan M, Abd Elsame M. Median cervical corpectomy for cervical myelopathy associated with ossified posterior longitudinal ligament. *Trends Med Res.* 2013;8:1-15.
- Hou X, Lu S, Wang B, Kong C, Hu H. Morphologic characteristics of the deep cervical paraspinal muscles in patients with single-level cervical spondylotic myelopathy. *World Neurosurg*. 2020;134:e166-e171. doi: 10.1016/j.wneu.2019.09.162
- 42. Jain SSS, Singh S, Joshi AK, Pamecha C, Dave B, Patel P. Comparative study of anterior versus posterior decompression in elderly patients of cervical myelopathy with co-morbid conditions. *Eur J Orthop Surg Traumatol.* 2009;19:397-401.
- 43. Kang X, Xiang S, Pei S, Li S, Wang Q. Limited laminectomy with lateral mass screw fixation versus normal laminetomy for multi-segment cervical spondylotic myelopathy: a comparative analysis. *Int J Clin Exp Med.* 2020;13(4):2295-2303.
- Kato M, Nakamura H, Konishi S et al. Effect of preserving paraspinal muscles on postoperative axial pain in the selective cervical laminoplasty. *Spine (Phila Pa 1976)*. 2008;33(14): E455-E469. doi: 10.1097/BRS.0b013e318178e607
- Kawakita E, Kasai Y, Uchida A. Low back pain and cervical spondylotic myelopathy. *J Orthop Surg.* 2009;17(2):187-189. doi: 10.1177/230949900901700213
- 46. Kim CR, Yoo JY, Lee SH, Lee DH, Rhim SC. Gait analysis for evaluating the relationship between increased signal intensity on t2-weighted magnetic resonance imaging and gait function in cervical spondylotic myelopathy. *Arch Phys Med Rehabil*. 2010; 91(10):1587-1592. doi: 10.1016/j.apmr.2010.07.008
- Kim IS, Kim YI, Hong JT, Lee DS. Rationales for a Urodynamic Study in Patients with Cervical Spondylotic Myelopathy. *World Neurosurg*. 2018;91(10):1587-1592. doi: 10.1016/j.wneu.2018.12.049
- Kim YJ, Oh SH, Yi HJ, Kim YS, Ko Y, Oh SJ. Myelopathy caused by soft cervical disc herniation: Surgical results and prognostic factors. *J Korean Neurosurg Soc.* 2007;42(6): 441-445. doi: 10.3340/jkns.2007.42.6.441
- Kiris T, Kilincer C. Cervical spondylotic myelopathy treated by oblique corpectomy: A prospective study. *Neurosurgery*. 2008; 62(3):674-682. doi: 10.1227/01.neu.0000317316.56235.a7
- 50. Kommu R, Sahu BP, Purohit AK. Surgical outcome in patients with cervical ossified posterior longitudinal ligament: A single

institutional experience. *Asian J Neurosurg*. 2014;9(4):196-202. doi: 10.4103/1793-5482.146602

- Kong W, Xin Z, Du Q, Cao G, Liao W. Anterior percutaneous fullendoscopic transcorporeal decompression of the spinal cord for single-segment cervical spondylotic myelopathy: The technical interpretation and 2 years of clinical follow-up. *J Orthop Surg Res.* 2019;14(1):461. doi: 10.1186/s13018-019-1474-5
- Konya D, Ozgen S, Gercek A, Pamir MN. Outcomes for combined anterior and posterior surgical approaches for patients with multisegmental cervical spondylotic myelopathy. *J Clin Neurosci.* 2009;16(3):404-409. doi: 10.1016/j.jocn.2008.07.070
- Lau D, Winkler EA, Than KD, Chou D, Mummaneni PV. Laminoplasty versus laminectomy with posterior spinal fusion for multilevel cervical spondylotic myelopathy: Influence of cervical alignment on outcomes. *J Neurosurg Spine*. 2017;27(5): 508-517. doi: 10.3171/2017.4.SPINE16831.
- Lo YL. The role of electrophysiology in the diagnosis and management of cervical spondylotic myelopathy. *Ann Acad Med Singap.* 2007;36(11):886-893.
- Misawa T, Kamimura M, Kinoshita T, Itoh H, Yuzawa Y, Kitahara J. Neurogenic bladder in patients with cervical compressive myelopathy. *J Spinal Disord Tech*. 2005;18(4): 315-320. doi: 10.1097/01.bsd.0000166638.31398.14
- 56. Moussellard HP, Meyer A, Biot D, Khiami F, Sariali E. Early neurological recovery course after surgical treatment of cervical spondylotic myelopathy: A prospective study with 2-year follow-up using three different functional assessment tests. *Eur Spine J.* 2014;23(7):1508-1514. doi: 10.1007/s00586-014-3315-x
- Niu S, Anastasio AT, Maidman SD, Faraj RR, Rhee JM. The frequency of various "myelopathic symptoms" in cervical myelopathy: Evaluation in a large surgical cohort. *Clin Spine Surg*. 2020;33(10):E448-E453. doi: 10.1097/BSD.000000000000968
- Rajasekaran S, Aiyer SN, Shetty AP, Kanna RM, Maheswaran A, Shetty JY. Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: A double-blinded, placebo-controlled randomised controlled trial. *Eur Spine J.* 2016;25(6):1830-1835. doi: 10.1007/s00586-015-4323-1
- Raslan F, Koehler S, Berg F et al. Vertebral body replacement with PEEK-cages after anterior corpectomy in multilevel cervical spinal stenosis: A clinical and radiological evaluation. *Arch Orthop Trauma Surg.* 2014;134(5):611-618. doi: 10.1007/ s00402-014-1972-1
- Revanappa KK, Moorthy RK, Alexander M, Rajshekhar V. Recovery of sympathetic skin response after central corpectomy in patients with moderate and severe cervical spondylotic myelopathy. *Br J Neurosurg*. 2017;31(2):199-204. doi: 10.1080/ 02688697.2016.1206178
- Scholler K, Siller S, Brem C, Lutz J, Zausinger S. Diffusion tensor imaging for surgical planning in patients with cervical spondylotic myelopathy. *J Neurol Surg Cent Eur Neurosurg*. 2020;81(1):1-9. doi: 10.1055/s-0039-1691822
- 62. Sinha S, Jagetia A. Bilateral open-door expansive laminoplasty using unilateral posterior midline approach with preservation of

posterior supporting elements for management of cervical myelopathy and radiculomyelopathy–analysis of clinical and radiological outcome and surgical technique. *Acta Neurochir* (*Wien*). 2011;153(5):975-984. doi: 10.1007/s00701-010-0872-6

- Sugawara T, Hirano Y, Higashiyama N, Mizoi K. Limaprost alfadex improves myelopathy symptoms in patients with cervical spinal canal stenosis. *Spine (Phila Pa 1976)*. 2009;34(6): 551-555. doi: 10.1097/BRS.0b013e31819a84ec
- 64. Thakar S, Christopher S, Rajshekhar V. Quality of life assessment after central corpectomy for cervical spondylotic myelopathy: Comparative evaluation of the 36-item short form health survey and the world health organization quality of lifebref. *J Neurosurg Spine*. 2009;11(4):402-412. doi: 10.3171/2009.4.SPINE08749
- Thakar S, Rajshekhar V. Evaluation of pain as a preferencebased health status measure in patients with cervical spondylotic myelopathy undergoing central corpectomy. *Acta Neurochir* (*Wien*). 2012;154(2):335-340. doi: 10.1007/s00701-011-1229-5
- 66. Turel MK, Sarkar S, Prabhu K, Daniel RT, Jacob KS, Chacko AG. Reduction in range of cervical motion on serial long-term follow-up in patients undergoing oblique corpectomy for cervical spondylotic myelopathy. *Eur Spine J.* 2013;22(7): 1509-1516. doi: 10.1007/s00586-013-2724-6
- Williams KE, Paul R, Dewan Y. Functional outcome of corpectomy in cervical spondylotic myelopathy. *Indian J Orthop*. 2009;43(2):205-209. doi: 10.4103/0019-5413.50855
- Vitzthum HE, Dalitz K. Analysis of five specific scores for cervical spondylogenic myelopathy. *Eur Spine J.* 2007;16(12): 2096-2103. doi: 10.1007/s00586-007-0512-x
- Wang L, Liu CY, Tian JW, Tian X, Dong SH, Zhao QH. Combined single-level subtotal corpectomy and decompression for cervical spondylotic myelopathy treatment. *ANZ J Surg.* 2012;82(5):342-347. doi: 10.1111/j.1445-2197.2011.05996.x
- 70. Wei L, Cao P, Xu C et al. The relationship between preoperative factors and the presence of intramedullary increased signal intensity on T2-weighted magnetic resonance imaging in patients with cervical spondylotic myelopathy. *Clin Neurol Neurosurg*. 2019;178:1-6. doi: 10.1016/j.clineuro.2019.01.006
- Zhang RJ, Shen CL, Zhang JX et al. Clinical features and surgical outcomes of cervical spondylotic myelopathy in patients of different ages: A retrospective study. *Spinal Cord*. 2018;56(1):7-13. doi: 10.1038/sc.2017.91
- Zhang Y, Liu H, Yang H, Pi B. Relationship between sagittal balance and axial symptoms in patients with cervical spondylotic myelopathy treated with anterior cervical discectomy and fusion. *J Invest Surg.* 2020;33(5):404-411. doi: 10.1080/ 08941939.2018.1524948
- Zhou F, Huang M, Wu L et al. Altered perfusion of the sensorimotor cortex in patients with cervical spondylotic myelopathy: an arterial spin labeling study. *J Pain Res.* 2018;11: 181-190. doi: 10.2147/JPR.S148076
- Zhou FQ, Tan YM, Wu L, Zhuang Y, He LC, Gong HH. Intrinsic functional plasticity of the sensory-motor network in patients with cervical spondylotic myelopathy. *Sci Rep.* 2015;5:9975. doi: 10.1038/srep09975

- Chacko AG, Joseph M, Turel MK, Prabhu K, Daniel RT, Jacob KS. Multilevel oblique corpectomy for cervical spondylotic myelopathy preserves segmental motion. *Eur Spine J.* 2012; 21(7):1360-1367. doi: 10.1007/s00586-011-2137-3
- 76. Chacko AG, Daniel RT. Multilevel cervical oblique corpectomy in the treatment of ossified posterior longitudinal ligament in the presence of ossified anterior longitudinal ligament. *Spine (Phila Pa 1976)*. 2007;32(20):E575-E580. doi: 10.1097/ BRS.0b013e31814b84fe
- 77. Zipser CM, Fehlings MG, Margetis K, AO Spine RECODE DCM Steering Committee and Members of the Diagnostic Criteria Working Group et al. Proposing a framework to understand the role of imaging in degenerative cervical myelopathy: enhancement of MRI protocols needed for accurate diagnosis and evaluation. *Spine (Phila Pa 1976)*. 2022;47(17): 1259-1262. doi: 10.1097/BRS.00000000004389
- Kalsi-Ryan S, Rienmueller AC, Riehm L et al. Quantitative assessment of gait characteristics in degenerative cervical myelopathy: A prospective clinical study. *J Clin Med.* 2020;9(3): 752. doi: 10.3390/jcm9030752
- Tetreault L, Garwood P, Gharooni AA et al. Improving assessment of disease severity and strategies for monitoring progression in degenerative cervical myelopathy [AO spine RECODE-DCM research priority number 4]. *Global Spine J*. 2022;12(1_suppl):64S-77S. doi: 10.1177/21925682211063854
- Kuhtz-Buschbeck JP, Johnk K, Mader S, Stolze H, Mehdorn M. Analysis of gait in cervical myelopathy. *Gait Posture*. 1999; 9(3):184-189. doi: 10.1016/s0966-6362(99)00015-6
- Haddas R, Patel S, Arakal R, Boah A, Belanger T, Ju KL. Spine and lower extremity kinematics during gait in patients with cervical spondylotic myelopathy. *Spine J.* 2018;18(9): 1645-1652. doi: 10.1016/j.spinee.2018.04.006
- Lee JH, Lee SH, Seo IS. The characteristics of gait disturbance and its relationship with posterior tibial somatosensory evoked potentials in patients with cervical myelopathy. *Spine (Phila Pa 1976)*. 2011;36(8):E524-E530. doi: 10.1097/BRS.0b013e3181f412d9
- 83. Malone A, Meldrum D, Bolger C. Gait impairment in cervical spondylotic myelopathy: Comparison with age- and

gender-matched healthy controls. *Eur Spine J*. 2012;21(12): 2456-2466. doi: 10.1007/s00586-012-2433-6

- Suzuki E, Nakamura H, Konishi S, Yamano Y. Analysis of the spastic gait caused by cervical compression myelopathy. *J Spinal Disord Tech.* 2002;15(6):519-522. doi: 10.1097/ 00024720-200212000-00015
- Lannon M, Kachur E. Degenerative cervical myelopathy: Clinical presentation, assessment, and natural history. *J Clin Med.* 2021;10(16):3626. doi: 10.3390/jcm10163626
- Reid MC, Eccleston C, Pillemer K. Management of chronic pain in older adults. *BMJ*. 2015;350:h532. doi: 10.1136/bmj.h532
- Goode AP, Freburger J, Carey T. Prevalence, practice patterns, and evidence for chronic neck pain. *Arthritis Care Res.* 2010; 62(11):1594-1601. doi: 10.1002/acr.20270
- Bot SD, van der Waal JM, Terwee CB et al. Incidence and prevalence of complaints of the neck and upper extremity in general practice. *Ann Rheum Dis.* 2005;64(1):118-123. doi: 10. 1136/ard.2003.019349
- Smith ZA, Barry AJ, Paliwal M, Hopkins BS, Cantrell D, Dhaher Y. Assessing hand dysfunction in cervical spondylotic myelopathy. *PLoS One*. 2019;14(10):e0223009. doi: 10.1371/ journal.pone.0223009
- Ono K, Ebara S, Fuji T, Yonenobu K, Fujiwara K, Yamashita K. Myelopathy hand. New clinical signs of cervical cord damage. *J Bone Joint Surg Br.* 1987;69(2):215-219. doi: 10.1302/0301-620X.69B2.3818752
- Singjam A, Charoentanyarak K, Saengsuwan J. Prevalence and predictive factors for bilateral carpal tunnel syndrome by electrodiagnosis: A retrospective study. *PLoS One*. 2021;16(12): e0260578. doi: 10.1371/journal.pone.0260578
- 92. Feloney MP, Leslie SW. *Bladder Sphincter Dyssynergia*. Treasure Island. FL: StatPearls; 2022.
- Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. *Int J Impot Res.* 2003;15(2):87-89. doi: 10.1038/sj.ijir. 3900948
- Comarr AE. Sexual function among patients with spinal cord injury. Urol Int. 1970;25(2):134-168. doi: 10.1159/000279669